<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1611211329
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DAPTOMYCIN BOS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAPTOMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        350
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        173.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gland Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gland Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Daptomycin BOS is daptomycin. Daptomycin is an antibacterial that can stop the growth of certain bacteria. Daptomycin BOS is used in adults and in children and adolescents (age from 1 to 17 years) to treat infections of the skin and the tissues below the skin. It is also used to treat infections in the blood when associated with skin infection.</p><p>Daptomycin BOS is also used in adults to treat infections in the tissues that line the inside of the heart (including heart valves) which are caused by a type of bacteria called <em>Staphylococcus aureus</em>. It is also used to treat infections in the blood caused by the same type of bacteria when associated with heart infection.</p><p>Depending on the type of infection(s) that you have, your doctor may also prescribe other antibacterials while you are receiving treatment with Daptomycin BOS.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Daptomycin BOS</strong></p><p>If you are allergic to daptomycin or to sodium hydroxide or to any of the other ingredients of this medicine (listed in section 6).</p><p>If this applies to you, tell your doctor or nurse. If you think you may be allergic, ask your doctor or nurse for advice.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before you are given this medicine:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have previously had kidney problems. Your doctor may need to change the dose of Daptomycin BOS (See section 3 of this leaflet).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Occasionally, patients receiving daptomycin may develop tender or aching muscles or muscle weakness (see section 4 of this leaflet for more information). If this happens, tell your doctor. Your doctor will make sure you have a blood test and will advise whether or not to continue with Daptomycin BOS. The symptoms generally go away within a few days of stopping Daptomycin BOS.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are very overweight. There is a possibility that your blood levels of daptomycin in could be higher than those found in persons of average weight and you may need careful monitoring in case of side effects.</p><p>If any of these applies to you, tell your doctor or nurse before you are given Daptomycin BOS.</p><p>&nbsp;</p><p>Tell your doctor straight away if you develop any of the following symptoms:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious, acute allergic reactions have been observed in patients treated with nearly all antibacterial agents, including Daptomycin BOS. Tell a doctor or a nurse straight away if you experience symptoms suggestive of allergic reaction, such as wheezing, difficulty breathing, swelling of the face, neck and throat, rashes and hives, fever (see section 4 of this leaflet for more information).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unusual tingling or numbness of the hands or feet, loss of feeling or difficulties with movements. If this happens, tell your doctor who will decide whether you should continue the treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, especially if you notice blood or mucus, or if diarrhoea becomes severe or persistent.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worsening fever, cough or difficulty breathing. These may be signs of a rare but serious lung disorder called eosinophilic pneumonia. Your doctor will check the condition of your lungs and decide whether or not you should continue Daptomycin BOS treatment.</p><p>&nbsp;</p><p>Daptomycin BOS may interfere with laboratory tests that measure how well your blood is clotting. The results can suggest poor blood clotting when, in fact, there is no problem. Therefore, it is important that your doctor takes into account that you are receiving Daptomycin BOS. Please inform your doctor that you are on treatment with Daptomycin BOS.</p><p>&nbsp;</p><p>Your doctor will perform blood tests to monitor the health of your muscles both before you start treatment and frequently during treatment with Daptomycin BOS.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Daptomycin BOS should not be administered to children below one year of age as studies in animals have indicated that this age group may experience severe side effects.</p><p>&nbsp;</p><p>Use in elderly</p><p>People over the age of 65 can be given the same dose as other adults, provided their kidneys are working well.</p><p>&nbsp;</p><p><strong>Other medicines and Daptomycin BOS</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. It is particularly important that you mention the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines called statins or fibrates (to lower cholesterol) or ciclosporin (a medicinal product used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis). It is possible that the risk of side effects affecting the muscles may be higher when any of these medicines (and some others that can affect muscles) is taken during treatment with Daptomycin BOS. Your doctor may decide not to give you Daptomycin BOS or to stop the other medicine for a while.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain killing medicines called non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors (e.g. celecoxib). These could interfere with the effects of Daptomycin BOS in the kidney.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral anti-coagulants (e.g. warfarin), which are medicines that prevent blood from clotting. It may be necessary for your doctor to monitor your blood clotting times.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Daptomycin BOS is not usually given to pregnant women. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.</p><p>&nbsp;</p><p>Do not breast-feed if you are receiving Daptomycin BOS, because it may pass into your breast milk and could affect the baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Daptomycin has no known effects on the ability to drive or use machines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Daptomycin BOS will usually be given to you by a doctor or a nurse.</p><p>&nbsp;</p><p><strong>Adults (18 years of age and above)</strong></p><p>The dose will depend on how much you weigh and the type of infection being treated. The usual dose for adults is 4 mg for every kilogram (kg) of body weight once daily for skin infections or 6&nbsp;mg for every kg of body weight once daily for a heart infection or a blood infection associated with skin or heart infection. In adult patients, this dose is given directly into your blood stream (into a vein), either as an infusion lasting about 30 minutes or as an injection lasting about 2&nbsp;minutes. The same dose is recommended in people aged over 65 years provided their kidneys are working well. If your kidneys do not work well, you may receive Daptomycin BOS less often, e.g. once every other day. If you are receiving dialysis, and your next dose of Daptomycin BOS is due on a dialysis day, you will be usually given Daptomycin BOS after the dialysis session.</p><p>&nbsp;</p><p><strong>Children and adolescents (1 to 17 years of age)</strong></p><p>The dose for children and adolescents (1 to 17 years of age) will depend on the age of patient and the type of infection being treated. This dose is given directly into the blood stream (into a vein), as an infusion lasting about 30-60 minutes.</p><p>A course of treatment usually lasts for 1 to 2 weeks for skin infections. For blood or heart infections and skin infections your doctor will decide how long you should be treated.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most serious side effects are described below:</p><p><strong>Very rare serious side effects</strong> (may affect up to 1 in 10,000 people)</p><p>A hypersensitivity reaction (serious allergic reaction including anaphylaxis, angioedema, drug rash with eosinophilia and systemic symptoms (DRESS)) has been reported, in some cases during administration of daptomycin. This serious allergic reaction needs immediate medical attention. Tell your doctor or nurse straight away if you experience any of the following symptoms:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain or tightness,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash with blistering, sometimes affecting the mouth and genitals,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling around throat,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid or weak pulse,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wheezing,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering or trembling,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flushes,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metallic taste.</p><p>&nbsp;</p><p>Tell your doctor straight away if you experience unexplained muscle pain, tenderness, or weakness. In very rare cases (reported in less than 1 in every 10,000 patients), muscle problems can be serious, including muscle breakdown (rhabdomyolysis), which can result in kidney damage.</p><p>&nbsp;</p><p><strong>Serious side effects with frequency not known</strong> (frequency cannot be estimated from the available data)</p><p>A rare but potentially serious lung disorder called eosinophilic pneumonia has been reported in patients given daptomycin, mostly after more than 2 weeks of treatment. The symptoms can include difficulty breathing, new or worsening cough, or new or worsening fever. If you experience these symptoms, tell your doctor or nurse straight away.</p><p>If you experience raised or fluid-filled skin spots over a large area of your body, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p>The most frequently reported side effects are described below:</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections such as thrush,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased number of red blood cells (anaemia),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, anxiety, difficulty in sleeping,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, weakness (asthenia),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High or low blood pressure,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, abdominal pain,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, feeling sick (nausea) or being sick (vomiting),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flatulence,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal swelling or bloating,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash or itching,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain, itchiness or redness at the site of infusion,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in arms or legs,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood testing showing higher levels of liver enzymes or creatine phosphokinase (CPK).</p><p>&nbsp;</p><p>Other side effects which may occur following daptomycin treatment are described below:</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood disorders (e.g. increased number of small blood particles called platelets, which may increase the tendency for blood clotting, or higher levels of certain types of white blood cells),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or numbness of the hands or feet, taste disturbance,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trembling,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in heart rhythm, flushes,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion (dyspepsia), inflammation of the tongue,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy rash of skin,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain, cramping, or weakness, inflammation of the muscles (myositis), joint pain,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation and irritation of the vagina,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General pain or weakness, tiredness (fatigue),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood test showing increased levels of blood sugar, serum creatinine, myoglobin, or lactate dehydrogenase (LDH), prolonged blood clotting time or imbalance of salts,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy eyes.</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and eyes,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prothrombin time prolonged.</p><p>&nbsp;</p><p><strong>Frequency not known</strong> (frequency cannot be estimated from the available data)</p><p>Antibacterial-associated colitis, including pseudomembranous colitis (severe or persistent diarrhoea containing blood and/or mucus, associated with abdominal pain or fever), easy bruising, bleeding gums, or nosebleeds</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and the label after EXP. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C‑8&deg;C)</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient is daptomycin. One vial of powder contains 350&nbsp;mg daptomycin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Daptomycin BOS is a pale yellow to light brown lyophilised cake or powder for injection containing. The product is packed as 350 mg of Daptomycin in 15 mL USP Type I clear glass lyo vial, stoppered with 20 mm dark grey bromobutyl rubber stoppers and sealed with 20 mm aluminium flip-off seals.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MAH and Secondary packaging:</p><p>Boston Oncology Arabia</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p><p>&nbsp;</p><p>Full Manufacturing and Primary Packaging:</p><p>Gland Pharma Limited</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last updated in 01/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في <strong>دابتومايسين بي او اس</strong> هي دابتومايسين. وهي مادة مضادة للجراثيم يمكنها إيقاف نمو بعض الجراثيم. يُستخدم <strong>دابتومايسين بي او اس</strong> لدى البالغين والأطفال والمراهقين (بعمر من 1 إلى 17 سنة) لمعالجة التهابات الجلد والأنسجة تحت الجلد.</p><p dir="RTL">ويُستخدم أيضاً لمعالجة الالتهابات في الدم عندما يُصاحبها التهاب في الجلد.</p><p dir="RTL">يُستخدم <strong>دابتومايسين بي او اس</strong> أيضاً لدى البالغين لمعالجة الالتهابات في الأنسجة التي تُبطّن داخل القلب (بما في ذلك صمامات القلب) التي يُسببها نوع من الجراثيم يُسمى <em>المكورات العنقودية الذهبية</em>.</p><p dir="RTL">كما أنه يُستخدم أيضاً لمعالجة الالتهابات في الدم الناجمة عن نفس النوع من الجراثيم عندما يُصاحبها التهاب في القلب.</p><p dir="RTL">واعتماداً على نوع الالتهاب (العدوى) التي لديك، قد يصف طبيبك أيضاً مُضادات جراثيم أخرى أثناء تلقيك المعالجة بدواء <strong>دابتومايسين بي او اس</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا ينبغي أن تُعطى <strong>دابتومايسين بي او اس</strong></p><p dir="RTL">إذا كنت تتحسس من مادة دابتومايسين أو هايدروكسيد الصوديوم أو أيّاً من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">إذا كان هذا ينطبق عليك، أخبر طبيبك أو ممرضتك. إذا كنت تعتقد أن لديك حساسية، اسأل طبيبك أو ممرضتك للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو ممرضتك قبل إعطائك هذا الدواء:</p><p dir="RTL">&bull; إذا كان لديك أو سبق أن كان لديك مشاكل في الكلى. قد يحتاج طبيبك لتغييرجرعة <strong>دابتومايسين بي او اس</strong> (انظر القسم 3 من هذه النشرة).</p><p dir="RTL">&bull; في بعض الأحيان، قد يصاب المرضى الذين يتلقون دابتتومايسين بعَرَض أو ألم في العضلات أو ضعف العضلات (انظر القسم 4 من هذه النشرة لمزيد من المعلومات). إذا حدث هذا، أخبر طبيبك. سيتأكد طبيبك من فحص الدم وسيقدم لك المشورة بشأن استمرار أو عدم استمرار تناول <strong>دابتومايسين بي او اس.</strong> وبشكلٍ عام تزول الأعراض خلال بضعة أيام من التوقف عن استخدام <strong>دابتومايسين بي او اس</strong>.</p><p dir="RTL">إذا كنت بديناً جداً. هناك احتمال أن مستويات دمك من دابتومايسين قد تكون أعلى من تلك الموجودة في الأشخاص ذوي الوزن المعتدل ​​وقد تحتاج إلى مراقبة دقيقة في حالة التأثيرات الجانبية.</p><p dir="RTL">إذا كان أيّاً من هذه الأمور ينطبق عليك، أخبر طبيبك أو ممرضتك قبل أن يُعطى لك دواء <strong>دابتومايسين بي او اس</strong>.</p><p dir="RTL">أخبر طبيبك في الحال إذا واجهت أيٍّ من الأعراض التالية:</p><p dir="RTL">&bull; لوحظت تفاعلات تحسسية حادة وخطيرة لدى المرضى الذين عولجوا تقريباً بكل عوامل مضادات الجراثيم، بما فيها <strong>دابتومايسين بي او اس</strong>. أخبر الطبيب أو الممرضة حالاً إذا حدثت عندك أعراض توحي برد فعل تحسسي، مثل الصفير، صعوبة التنفس، تورُّم الوجه، العنق والحنجرة،&nbsp; طفح وقشعريرة، حمى (انظر القسم 4 من هذه النشرة لمزيدٍ من المعلومات).</p><p dir="RTL">&bull; إذا حدث لك، أيَّ وخزٍ أو خدرٍ غير عاديٍّ في اليدين أو القدمين، فقدان الشعور أو صعوبات في الحركات. أخبر طبيبك الذي سيقرر ما إذا كان يجب عليك متابعة المعالجة.</p><p dir="RTL">&bull; إسهال، خاصة إذا لاحظت وجود دم أو مخاط، أو إذا أصبح الإسهال شديداً أو مستمراً.</p><p dir="RTL">&bull; حمى جديدة أو متفاقمة، سعال أو صعوبة في التنفس. قد تكون هذه علامات نادرة لكنها اضطراب رئة خطير يسمى الالتهاب الرئوي الإيزونوفيلي. سيتحقق طبيبك من حالة رئتيك ويقرر ما إذا كان يجب عليك الاستمرار أو عدم الاستمرار بالمعالجة بدواء <strong>دابتومايسين بي او اس</strong>.</p><p dir="RTL">قد يتداخل <strong>دابتومايسين بي او اس</strong> مع الفحوصات المخبرية التي تقيس مدى تخثر الدم لديك.</p><p dir="RTL">يمكن أن توحي النتائج بتخثر دم ضعيف بينما، في الحقيقة، لا يوجد أية مشكلة. وبالتالي، فإنه من المهم أن يأخذ طبيبك بالاعتبار أنك تتلقى <strong>دابتومايسين بي او اس</strong>. رجاء أخبار طبيبك أنك تخضع للمعالجة بدواء <strong>دابتومايسين بي او اس</strong>.</p><p dir="RTL">سيقوم طبيبك بإجراء اختبارات الدم لمراقبة صحة عضلاتك قبل البدء بالمعالجة وأحياناً أثناء المعالجة بدواء <strong>دابتومايسين بي او اس</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا ينبغي أن يوصفَ <strong>دابتومايسين بي او اس</strong> للأطفال دون السنة الواحدة من العمر لأن الدراسات على الحيوانات أشارت أن مجموعة الأعمار هذه قد تواجه تأثيرات جانبية شديدة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام لدى كبار السن</strong></p><p dir="RTL">يمكن إعطاء الأشخاص الذين تزيد أعمارهم عن 65 سنة نفس جرعة البالغين، شرط أن تكون كليتيهم تعملان بشكل جيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى و دابتومايسين بي او اس</strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك إذا كنت تتناول، أو قد تناولت مؤخراً أو قد تأخذ أية أدوية أخرى.</p><p dir="RTL">من المهم بشكل خاص أن تذكُرَ ما يلي:</p><p dir="RTL">&bull; الأدوية التي تدعى الستاتين أو الألياف (لخفض الكوليسترول) أو السيكلوسبورين (دواء يُستخدم في عملية الزرع لمنع رفض الأعضاء أو لحالات أخرى، مثل التهاب المفاصل الروماتيزمي أو التهاب الجلد التأتبي). يُحتمل أن يكون خطر التأثيرات الجانبية المؤثرة على العضلات أعلى عندما يتم تناول أيٍّ من هذه الأدوية (والبعض الآخر التي يمكن أن تؤثر على العضلات) أثناء المعالجة بدواء <strong>دابتومايسين بي او اس</strong>. قد يُقرر طبيبك عدم إعطائك <strong>دابتومايسين بي او اس</strong> أو أن يوقف الأدوية الأخرى لفترة من الزمن.</p><p dir="RTL">&bull; الأدوية المسكنة للألم المسماة أدوية مضادة للالتهابات غير الستيروئيدية (NSAIDs) أو مثبطات COX-2 (مثل سيليكوكسيب). هذه قد تتداخل مع تأثيرات <strong>دابتومايسين بي او اس</strong> في الكلى.</p><p dir="RTL">&bull; مضادات التخثر الفموية (مثل وارفارين)، وهي أدوية تمنع الدم من التجلط.</p><p dir="RTL">قد يكون من الضروري لطبيبك مراقبة أزمنة تخثر دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يُعطى عادةً <strong>دابتومايسين بي او اس</strong> للحوامل. إذا كنتِ حاملاً أو مرضعةً،</p><p dir="RTL">أو تظنين أنكِ قد تكونين حاملاً أو تخططينَ لإنجابِ طفلٍ، اطلبي نصيحة طبيبك أو الصيدلي قبل أن يُعطى إليكِ هذا الدواء.</p><p dir="RTL">لا تُرضعي من حليبكِ إذا كنتِ تتلقينَ <strong>دابتومايسين بي او اس</strong>، لأنه قد ينتقل إلى حليبك ويمكن أن يؤثر على الطفل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>دابتومايسين بي او اس</strong> ليس له تأثيرات معروفة على قدرة القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم عادةً إعطاء <strong>دابتومايسين بي او اس</strong> لك من قبل طبيب أو ممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون (18 سنة من العمر فما فوق)</strong></p><p dir="RTL">تعتمد الجرعة على مقدار وزنك ونوع الالتهاب الذي يتم معالجته. الجرعة المعتادة للبالغين هي 4 ملغ لكل كيلوغرام (كغ) واحد من وزن الجسم مرة واحدة يومياً لالتهابات الجلد أو 6 ملغ لكل كيلوغرام (كغ) واحد من وزن الجسم مرة واحدة يومياً لالتهاب القلب أو التهاب الدم المصحوبة بالتهاب الجلد&nbsp; أو القلب. في المرضى البالغين، تُعطى هذه الجرعة مباشرة في مجرى الدم</p><p dir="RTL">(في الوريد)، إما بالتنقيط لفترة 30 دقيقة تقريباً أو كحقنة في فترة دقيقتين تقريباً. يُنصح بذات الجرعة في الأشخاص الذين تزيد أعمارهم عن 65 سنة، شرط أن تكون الكلى عندهم تعمل بشكل جيد. إذا كانت كليتيك لا تعمل جيداً، فقد تتلقى القليل من <strong>دابتومايسين بي او اس </strong>على الأغلب، مثل مرة كل يومين. إذا كنت تتلقى غسيل الكلى، وجرعتك التالية من <strong>دابتومايسين بي او اس</strong> موعدها في يوم الغسيل، سوف تُعطى عادةً <strong>دابتومايسين بي او اس</strong> بعد جلسة الغسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون (من عمر 1 إلى 17 سنة)</strong></p><p dir="RTL">الجرعة للأطفال والمراهقين (من عمر 1 إلى 17 سنة) سوف تعتمد على عمر المريض ونوع الالتهاب الذي تتم معالجته. يتم إعطاء هذه الجرعة مباشرة في مجرى الدم (في الوريد)، بالتسريب الذي يدوم حوالي 30-60 دقيقة.</p><p dir="RTL">تستغرق دورة المعالجة عادةً من أسبوع إلى أسبوعين للالتهابات الجلدية. ولالتهابات الدم أو القلب والتهابات الجلد سيقرر طبيبك المدة اللازمة لمعالجتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيراتٍ جانبيةٍ، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL">التأثيرات الجانبية الأكثر خطورةً موصوفة أدناه:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية خطيرة نادرة جداً</strong> (قد تؤثر حتى في 1 من كل 10،000 شخص)</p><p dir="RTL">لقد تم الإبلاغ عن رد فعل فرط حساسية (رد فعل تحسسي خطير يشمل حساسية مفرطة، وذمة وعائية، طفح دوائي مع فرط الحمضات وأعراض جهازية &quot;&quot;DRESS)، وفي بعض الحالات أثناء تناول دابتومايسين. رد الفعل التحسسي الخطير هذا يحتاج إلى عناية طبية فورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو ممرضتك فوراً إذا واجهتك أيّاً من الأعراض التالية:</p><p dir="RTL">&bull; ألم في الصدر أو ضيق،</p><p dir="RTL">&bull; طفح مع تقرحات، تؤثر أحياناً على الفم والأعضاء التناسلية،</p><p dir="RTL">&bull; تورُّم حول الحلق،</p><p dir="RTL">&bull; نبض سريع أو ضعيف،</p><p dir="RTL">&bull; صفير،</p><p dir="RTL">&bull; حمى،</p><p dir="RTL">&bull; ارتجاف أو رجفة،</p><p dir="RTL">&bull; هبّات ساخنة،</p><p dir="RTL">&bull; دوخة،</p><p dir="RTL">&bull; إغماء،</p><p dir="RTL">&bull; طعم معدني.</p><p dir="RTL">أخبر طبيبك في الحال إذا حصل معك ألم غير معروف في العضلات، وهن أو ضعف. في حالات نادرة جداً (تم الإبلاغ عنها في أقل من 1 من كل 10،000 مريض)، مشاكل في العضلات ربما تكون خطيرة، بما في ذلك انهيار العضلات (انحلال الرابدوات)، والتي قد تتسبَّب بتلف الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الخطيرة غير معروفة التكرار</strong> (لا يمكن تقدير تكرارها من البيانات المتاحة).</p><p dir="RTL">قد تم الإبلاغ عن اضطراب نادر في الرئة إلا أنه خطير يسمى الالتهاب الرئوي اليوزيني في المرضى الذين يُعطون دابتومايسين، معظمهم بعد أكثر من أسبوعين من المعالجة.</p><p dir="RTL">يمكن أن تشمل الأعراض صعوبة في التنفس، سعال جديد أو متفاقم، أو حمى جديدة أو متفاقمة. إذا واجهتك هذه الأعراض، أخبر طبيبك أو ممرضتك فوراً.</p><p dir="RTL">إذا حصل معك بقع جلدية منتفخة أو مملوءة بالسوائل على مساحة كبيرة من جسمك، أخبر طبيبك أو ممرضتك في الحال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التأثيرات الجانبية الأكثر شيوعاً موصوفة أدناه:</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة</strong> (قد تؤثر حتى في 1&nbsp; من كل 10 أشخاص)</p><p dir="RTL">&bull; التهابات فطرية مثل مرض القلاع،</p><p dir="RTL">&bull; التهاب المسالك البولية،</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم)،</p><p dir="RTL">&bull; دوخة، قلق، صعوبة النوم،</p><p dir="RTL">&bull; صداع راس،</p><p dir="RTL">&bull; حمى، ضعف (وهن)،</p><p dir="RTL">&bull; ضغط دم مرتفع أو منخفض،</p><p dir="RTL">&bull; إمساك، ألم بطن،</p><p dir="RTL">&bull; إسهال، شعور بالمرض (غثيان) أو كونك مريض (قيء)،</p><p dir="RTL">&bull; انتفاخ،</p><p dir="RTL">&bull; تورُّم بطن أو تطبُّل،</p><p dir="RTL">&bull; طفح جلدي أو حكة،</p><p dir="RTL">&bull; ألم أو حكة أو احمرار في موضع التسريب،</p><p dir="RTL">&bull; ألم في الذراعين أو الساقين،</p><p dir="RTL">&bull; فحص دم يُظهر مستويات أعلى من إنزيمات الكبد أو فسفوكيناز الكرياتين (CPK).</p><p dir="RTL">&nbsp;</p><p dir="RTL">التأثيرات الجانبية الأخرى التي قد تحدث عقب المعالجة بدواء دابتومايسين موصوفة أدناه:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية غير الشائعة</strong> (قد تؤثر حتى في 1 من كل 100 شخص)</p><p dir="RTL">&bull; اضطرابات الدم (مثل زيادة عدد جزيئات الدم الصغيرة التي تسمى الصفائح الدموية، والتي قد تُحدث زيادة الميل لتخثر الدم، أو مستويات أعلى لأنواع معينة من خلايا الدم البيضاء)،</p><p dir="RTL">&bull; قلة الشهية،</p><p dir="RTL">&bull; وخز أو خدر في اليدين أو القدمين، اضطراب التذوق،</p><p dir="RTL">&bull; رجفان،</p><p dir="RTL">&bull; تغيُّرات في إيقاع القلب، إحمرار،</p><p dir="RTL">&bull; عسر هضم (عسر الهضم)، التهاب اللسان،</p><p dir="RTL">&bull; طفح جلدي حاك،</p><p dir="RTL">&bull; ألم عضلات، تشنج، أو ضعف، التهاب عضلات (التهاب العضلات)، ألم المفاصل،</p><p dir="RTL">&bull; مشاكل في الكلى،</p><p dir="RTL">&bull; التهاب وتهيج المهبل،</p><p dir="RTL">&bull; ألم أو ضعف عام، تعب (التعب)،</p><p dir="RTL">&bull; اختبار دم يُظهر مستويات مرتفعة من السكر في الدم، مصل الكرياتينين، مايوغلوبين، أو ديهايدروجيناز اللاكتات (LDH)، أو فترة تخثر دم طويلة أو عدم توازن الأملاح،</p><p dir="RTL">&bull; حكة في العيون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة</strong> (قد تؤثر حتى في 1 من كل 1000 شخص)</p><p dir="RTL">&bull; اصفرار الجلد والعينين،</p><p dir="RTL">&bull; زمن بروثرومبين مطوَّل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تكرار غير معروف</strong> (لا يمكن تقدير تكرارها من البيانات المتاحة)</p><p dir="RTL">التهاب قولون مرتبط بمضادات الجراثيم، بما في ذلك التهاب القولون الغشائي الكاذب (إسهال شديد أو مستمر حاوي على دم و/أو مخاط، مرتبط بألم بطن أو حمى)، كدمات سهلة، نزيف لثة، أو نزيف أنف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة واللصاقة بعد EXP. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull; يحفظ في البراد بدرجة حرارة (2 - 8 مئوية).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; العنصر الفعال هو دابتومايسين . تحتوي القارورة الواحدة على 350 ملغ&nbsp; من مسحوق دابتومايسين.</p><p dir="RTL">&bull; المكون الآخر هو هايدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دابتومايسين بي او اس هو </strong>قرص أو مسحوق أصفر شاحب إلى بني فاتح مجفف بالتجميد معد للحقن. وهو معبأ بكمية 350 ملغ من دابتومايسين في قارورة زجاجية صافية معقمة من النوع 1 وفق الدستور الأمريكي سعة 15 مل، مغلقة بسدادة مطاطية بروموبوتيل رمادية داكنة 20 مم ومختومة بختم ألمنيوم 20 مم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مالك حقوق التسويق والتغليف الثانوي:</p><p dir="RTL">شركة بوستن اونكولجي العربية</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL">ب&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصنيع الكامل والتغليف الأولي:</p><p dir="RTL">قلاند فارما</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في 1/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Daptomycin TBM
Daptomycin for injection, 350 mg/vial. 15 ml vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 350 mg of daptomycin. 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyophilised cake or powder for injection
Pale yellow to light brown lyophilised cake or powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin TBM is indicated for the treatment of the following infections (see sections 4.4 and 5.1).<br />&bull; Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).</p><p>&bull; Adult patients with right-sided infective endocarditis (RIE) due to&nbsp;Staphylococcus aureus. It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice. See sections 4.4 and 5.1.</p><p>&bull; Adult and paediatric (1 to 17 years of age) patients with&nbsp;Staphylococcus aureus&nbsp;bacteraemia (SAB).</p><p>In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.<br />Daptomycin is active against Gram positive bacteria only (see section 5.1).</p><p>In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Daptomycin TBM should be co-administered with appropriate antibacterial agent(s).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies in patients employed infusion of daptomycin over at least 30 minutes.</p><p>There is no clinical experience in patients with the administration of daptomycin as an injection over 2 minutes.</p><p>This mode of administration was only studied in healthy subjects. However, when compared with the same doses given as intravenous infusions over 30 minutes there were no clinically important differences in the pharmacokinetics and safety profile of daptomycin (see also sections 4.8 and 5.2).</p><p>Posology</p><p>Adults</p><ul><li><p>cSSTI without concurrent SAB: Daptomycin TBM 4 mg/kg is administered once every</p><p>24 hours for 7-14 days or until the infection is resolved (see section 5.1).</p></li><li><p>cSSTI with concurrent SAB: Daptomycin TBM 6 mg/kg is administered once every 24 hours. See below for dose adjustments in patients with renal impairment.<br />The duration of therapy may need to be longer than 14 days in accordance with the perceived risk of&nbsp;complications in the individual patient.</p></li><li><p>Known or suspected RIE due to&nbsp;Staphylococcus aureus: Daptomycin TBM 6 mg/kg is&nbsp;administered once every 24 hours. See below for dose adjustments in patients with renal impairment. The duration of therapy should be in accordance with available official recommendations.</p><p>Daptomycin TBM is administered intravenously in 0.9% sodium chloride (see section 6.6). Daptomycin TBM should not be used more frequently than once a day.<br />Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) during treatment (see section 4.4).</p></li><li><p>Renal impairment</p><p>Daptomycin is eliminated primarily by the kidney.<br />Due to limited clinical experience (see table 1 and footnotes below) Daptomycin TBM should only be used in adult patients with any degree of renal impairment (CrCl &lt; 80 ml/min) when it is considered that the expected clinical benefit outweighs the potential risk. The response to treatment, renal function and creatine phosphokinase (CPK) levels should be closely monitored in all patients with any degree of renal impairment (see also sections 4.4 and 5.2). The dosage regimen for Daptomycin TBM in paediatric patients with renal impairment has not been established.</p></li></ul><p>&nbsp;</p><p><strong>Table 1: Dose adjustments in adult patients with renal impairment by indication and creatinine clearance</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication&nbsp;for&nbsp;use</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine&nbsp;clearance</strong></p></td><td style="vertical-align:top"><p><strong>Dose&nbsp;recommendation</strong></p></td><td style="vertical-align:top"><p><strong>Comments</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>cSSTI&nbsp;without&nbsp;SAB</p></td><td style="vertical-align:top"><p>&ge;30&nbsp;ml/min</p></td><td style="vertical-align:top"><p>4&nbsp;mg/kg&nbsp;once&nbsp;daily</p></td><td style="vertical-align:top"><p>See&nbsp;section&nbsp;5.1</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;30&nbsp;ml/min</p></td><td style="vertical-align:top"><p>4&nbsp;mg/kg&nbsp;every&nbsp;48&nbsp;hours</p></td><td style="vertical-align:top"><p>(1,2)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>RIE&nbsp;or&nbsp;cSSTI</p><p>associated&nbsp;with&nbsp;SAB</p></td><td style="vertical-align:top"><p>&ge;30&nbsp;ml/min</p></td><td style="vertical-align:top"><p>6&nbsp;mg/kg&nbsp;once&nbsp;daily</p></td><td style="vertical-align:top"><p>See&nbsp;section&nbsp;5.1</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;30&nbsp;ml/min</p></td><td style="vertical-align:top"><p>6&nbsp;mg/kg&nbsp;every&nbsp;48&nbsp;hours</p></td><td style="vertical-align:top"><p>(1,2)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>cSSTI&nbsp;=&nbsp;complicated&nbsp;skin&nbsp;and&nbsp;soft-tissue&nbsp;infections;&nbsp;SAB&nbsp;=&nbsp;<em>S.&nbsp;aureus&nbsp;</em>bacteraemia</p><p><!--[if !supportLists]-->(1)&nbsp;&nbsp;<!--[endif]-->The safety and efficacy of the dose interval adjustment have not been evaluated in controlled clinical trials and the recommendation is based on pharmacokinetic studies and modelling results (see sections 4.4 and 5.2).</p><p><!--[if !supportLists]-->(2)&nbsp;&nbsp;<!--[endif]-->The&nbsp;same&nbsp;dose&nbsp;adjustments,&nbsp;which&nbsp;are&nbsp;based&nbsp;on&nbsp;pharmacokinetic&nbsp;data&nbsp;in&nbsp;volunteers&nbsp;includingPK modelling results, are recommended for adult patients on haemodialysis (HD) or continuous ambulatory&nbsp;peritoneal&nbsp;&nbsp;dialysis&nbsp;&nbsp;(CAPD).&nbsp;&nbsp;Whenever&nbsp;&nbsp;possible,&nbsp;&nbsp;Daptomycin&nbsp;TBM&nbsp;&nbsp;should&nbsp;&nbsp;be</p><p>administered&nbsp;following&nbsp;the&nbsp;completion&nbsp;of&nbsp;dialysis&nbsp;on&nbsp;dialysis&nbsp;days&nbsp;(see&nbsp;section&nbsp;5.2)</p></td></tr></tbody></table><p>&nbsp;</p><ul><li>Hepatic impairment</li></ul><p>No dose adjustment is necessary when administering Daptomycin TBM to patients with mild or moderate hepatic impairment (Child-Pugh Class B) (see section 5.2). No data are available in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, caution should be exercised if Daptomycin TBM is given to such patients.</p><ul><li>Elderly patients</li></ul><p>The recommended doses should be used in elderly patients except those with severe renal impairment (see above and section 4.4).</p><ul><li>Paediatric patients (1 to 17 years of age)</li></ul><p>The recommended dosage regimens for paediatric patients based on age and indication are shown below.</p><p>&nbsp;</p><p><strong>Table&nbsp;2:&nbsp;Recommended&nbsp;dosage&nbsp;regimens&nbsp;for&nbsp;paediatric&nbsp;patients&nbsp;(1&nbsp;to&nbsp;17&nbsp;years&nbsp;of&nbsp;age)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p><strong>Age&nbsp;group</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Indication</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>cSSTI&nbsp;without&nbsp;SAB</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>cSSTI&nbsp;associated&nbsp;with&nbsp;SAB</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dosage&nbsp;Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Duration&nbsp;of</strong></p><p><strong>Therapy</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Dosage&nbsp;Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Duration&nbsp;of</strong></p><p><strong>Therapy</strong></p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;to&nbsp;years</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>5&nbsp;mg/kg&nbsp;&nbsp;&nbsp;&nbsp;once&nbsp;&nbsp;&nbsp;&nbsp;every</p><p>24&nbsp;hours&nbsp;infused&nbsp;over 30 minutes</p></td><td style="vertical-align:top"><p>Up&nbsp;to&nbsp;14&nbsp;days</p></td><td style="vertical-align:top"><p>7&nbsp;&nbsp;mg/kg&nbsp;&nbsp;once</p><p>24&nbsp;hours&nbsp;&nbsp;infused</p><p>30&nbsp;minutes</p></td><td style="vertical-align:top"><p>every&nbsp;over</p></td><td style="vertical-align:top"><p>(1)</p></td></tr><tr><td style="vertical-align:top"><p>7&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;years</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>7&nbsp;mg/kg&nbsp;once&nbsp;every 24&nbsp;hours&nbsp;infused&nbsp;over</p><p>30&nbsp;minutes</p></td><td style="vertical-align:top"><p>Up&nbsp;to&nbsp;14&nbsp;days</p></td><td style="vertical-align:top"><p>9&nbsp;mg/kg&nbsp;once24&nbsp;hoursinfused</p><p>30&nbsp;minutes</p></td><td style="vertical-align:top"><p>every&nbsp;over</p></td><td style="vertical-align:top"><p>(1)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>Age&nbsp;group</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Indication</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>cSSTI&nbsp;without&nbsp;SAB</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>cSSTI&nbsp;associated&nbsp;with&nbsp;SAB</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dosage&nbsp;Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Duration&nbsp;of</strong></p><p><strong>Therapy</strong></p></td><td style="vertical-align:top"><p><strong>Dosage&nbsp;Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Duration&nbsp;of</strong></p><p><strong>Therapy</strong></p></td></tr><tr><td style="vertical-align:top"><p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6&nbsp;years</p></td><td style="vertical-align:top"><p>9&nbsp;mg/kg&nbsp;once&nbsp;every 24&nbsp;hours&nbsp;infused&nbsp;over</p><p>60&nbsp;minutes</p></td><td style="vertical-align:top"><p>Up&nbsp;to&nbsp;14&nbsp;days</p></td><td style="vertical-align:top"><p>12&nbsp;mg/kg&nbsp;once&nbsp;every 24&nbsp;hours&nbsp;&nbsp;infused&nbsp;over</p><p>60&nbsp;minutes</p></td><td style="vertical-align:top"><p>(1)</p></td></tr><tr><td style="vertical-align:top"><p>1&nbsp;to&nbsp;&lt;&nbsp;2&nbsp;years</p></td><td style="vertical-align:top"><p>10&nbsp;mg/kg&nbsp;once&nbsp;every</p><p>24&nbsp;hours&nbsp;infused&nbsp;over 60 minutes</p></td><td style="vertical-align:top"><p>Up&nbsp;to&nbsp;14&nbsp;days</p></td><td style="vertical-align:top"><p>12&nbsp;mg/kg&nbsp;once&nbsp;every</p><p>24&nbsp;hours&nbsp;infused&nbsp;over 60 minutes</p></td><td style="vertical-align:top"><p>(1)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>cSSTI&nbsp;=&nbsp;complicated&nbsp;skin&nbsp;and&nbsp;soft-tissue&nbsp;infections;&nbsp;SAB&nbsp;=&nbsp;<em>S.&nbsp;aureus&nbsp;</em>bacteraemia;</p><p>(1) Minimum duration of Daptomycin TBM for paediatric SAB should be in accordance with the perceived risk of complications in the individual patient. The duration of Daptomycin TBM may need to be longer than 14 days in accordance with the perceived risk of complications in the individual patient. In the paediatric SAB study, the mean duration of IV daptomycin was 12 days, with&nbsp;a&nbsp;range&nbsp;of&nbsp;1&nbsp;to&nbsp;44&nbsp;days.&nbsp;The&nbsp;duration&nbsp;of&nbsp;therapy&nbsp;should&nbsp;be&nbsp;in&nbsp;accordance&nbsp;with&nbsp;availableofficial&nbsp;recommendations.</p></td></tr></tbody></table><p>Daptomycin TBM is administered intravenously in 0.9 % sodium chloride (see section 6.6). Daptomycin TBM should not be used more frequently than once a day.<br />Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) during treatment (see section 4.4).</p><p>Paediatric patients below the age of one year should not be given Daptomycin TBM due to the risk of potential effects on muscular, neuromuscular and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs (see section 5.3).</p><ul><li>Method of administration</li></ul><p>In adults, Daptomycin TBM is given by intravenous infusion (see section 6.6) and administered over a 30-minute period or by intravenous injection (see section 6.6) and administered over a 2-minute period.</p><p>In paediatric patients aged 7 to 17 years, Daptomycin TBM is given by intravenous infusion over a 30-minute period (see section 6.6). In paediatric patients aged 1 to 6 years,&nbsp;Daptomycin TBM is given by intravenous infusion over a 60-minute period (see section 6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, daptomycin, or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>If a focus of infection other than cSSTI or RIE is identified after initiation of daptomycin therapy consideration should be given to instituting alternative antibacterial therapy that has been&nbsp;demonstrated&nbsp;to&nbsp;be&nbsp;efficacious&nbsp;in&nbsp;thetreatment&nbsp;of&nbsp;the&nbsp;specific&nbsp;type&nbsp;of&nbsp;infection(s)&nbsp;present.</p><p>&nbsp;</p><p><u>Anaphylaxis/hypersensitivity&nbsp;reactions</u></p><p>Anaphylaxis/hypersensitivity reactions have been reported with daptomycin. If an allergic reaction to Daptomycin TBM occurs, discontinue use and institute appropriate therapy.</p><p>&nbsp;</p><p><u>Pneumonia</u></p><p>It&nbsp;has&nbsp;been&nbsp;demonstrated&nbsp;in&nbsp;clinical&nbsp;studies&nbsp;that&nbsp;daptomycin&nbsp;is&nbsp;not&nbsp;effective&nbsp;in&nbsp;the&nbsp;treatment&nbsp;of pneumonia. Daptomycin TBM is therefore not indicated for the treatment of pneumonia.</p><p>&nbsp;</p><p><u>RIE&nbsp;due&nbsp;to&nbsp;<em>Staphylococcus&nbsp;aureus</em></u></p><p>Clinical data on the use of daptomycin to treat RIE due to&nbsp;<em>Staphylococcus aureus&nbsp;</em>are limited to 19 adult patients (see section 5.1). The safety and efficacy of daptomycin in children and adolescents aged below 18 years with right-sided infective endocarditis (RIE) due to&nbsp;<em>Staphylococcus aureus&nbsp;</em>have not been established.</p><p>The efficacy of daptomycin in patients with prosthetic valve infections or with left-sided infective endocarditis due to&nbsp;<em>Staphylococcus aureus&nbsp;</em>has not been demonstrated.</p><p>&nbsp;</p><p><u>Deep-seated&nbsp;infections</u></p><p>Patients with deep-seated infections should receive any required surgical interventions (e.g. debridement, removal of prosthetic devices, valve replacement surgery) without delay.</p><p>&nbsp;</p><p><u>Enterococcal&nbsp;infections</u></p><p>There&nbsp;is&nbsp;insufficient&nbsp;evidence&nbsp;to&nbsp;be&nbsp;able&nbsp;to&nbsp;draw&nbsp;any&nbsp;conclusions&nbsp;regarding&nbsp;the&nbsp;possible&nbsp;clinical efficacy&nbsp;ofdaptomycin against infections&nbsp;due&nbsp;to enterococci,&nbsp;including&nbsp;<em>Enterococcus faecalis&nbsp;</em>and&nbsp;<em>Enterococcus&nbsp;faecium</em>.&nbsp;Inaddition,&nbsp;dose&nbsp;regimens&nbsp;of&nbsp;daptomycin&nbsp;that&nbsp;might&nbsp;be&nbsp;appropriate for the treatment of enterococcal infections, with or without bacteraemia, have not been identified. Failures with daptomycin in the treatment of enterococcal infections that were mostly accompanied by bacteraemia have been reported. In some instances, treatment failure has been associated with the selection of organisms with reduced susceptibility or frank resistance to daptomycin (see section 5.1).</p><p>The&nbsp;use&nbsp;of antibacterials may&nbsp;promote&nbsp;the&nbsp;overgrowth&nbsp;of&nbsp;non-susceptible&nbsp;micro-organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p>&nbsp;</p><p><u>Clostridium&nbsp;difficile-associated&nbsp;diarrhoea</u></p><p>Clostridium difficile-associated diarrhoea (CDAD) has been reported with daptomycin (see section 4.8). If CDAD is suspected or confirmed, Daptomycin&nbsp;TBM may need to be discontinued and appropriate treatment instituted as clinically indicated.</p><p>&nbsp;</p><p><u>Drug/laboratory&nbsp;test&nbsp;interactions</u></p><p>False prolongation of prothrombin time (PT) and elevation of international normalised ratio (INR)&nbsp;have&nbsp;beenobserved&nbsp;when&nbsp;certain&nbsp;recombinant&nbsp;thromboplastin&nbsp;reagents&nbsp;are&nbsp;utilised&nbsp;for the assay (see also section 4.5).</p><p>&nbsp;</p><p><u>Creatine&nbsp;phosphokinase&nbsp;and&nbsp;myopathy</u></p><p>Increases in plasma creatine phosphokinase (CPK; MM isoenzyme) levels associated with muscular pains and/or weakness and cases of myositis, myoglobinaemia and rhabdomyolysis have been reported during therapy with daptomycin (see also sections 4.5, 4.8 and 5.3). In clinical&nbsp;studies,&nbsp;marked&nbsp;increases&nbsp;in&nbsp;plasma&nbsp;CPK&nbsp;to&nbsp;&gt;5xUpperLimit&nbsp;of&nbsp;Normal&nbsp;(ULN)&nbsp;without muscle symptoms occurred more commonly in daptomycin-treated patients (1.9%) than in those that received comparators (0.5%). Therefore, it is recommended that:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Plasma&nbsp;CPK&nbsp;should&nbsp;be&nbsp;measured&nbsp;at&nbsp;baseline&nbsp;and&nbsp;at&nbsp;regular&nbsp;intervals&nbsp;(at&nbsp;least&nbsp;once&nbsp;weekly) during therapy in all patients.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->CPK&nbsp;should be&nbsp;measured more&nbsp;frequently (e.g. every&nbsp;2-3 days at least during the&nbsp;first two weeks of treatment) in patients who are at higher risk of developing myopathy. For example, patients with any degree of renal impairment (creatinine clearance &lt;80&nbsp;ml/min; see&nbsp;also&nbsp;section&nbsp;4.2),&nbsp;including&nbsp;those&nbsp;on&nbsp;haemodialysis&nbsp;or&nbsp;CAPD,and&nbsp;patients&nbsp;taking&nbsp;other medicinal products known to be associated with myopathy (e.g. HMG-CoA reductase inhibitors, fibrates and ciclosporin).</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->It cannot be ruled out that those patients with CPK greater than 5 times ULN at baseline may be at increased risk of further increases during daptomycin therapy. This should be taken into account when initiating daptomycin therapy and, if daptomycin is given, these patients should be monitored more frequently than once weekly.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Daptomycin TBM should not be administered to patients who are taking other medicinal products associated with myopathy unless it is considered that the benefit to the patient outweighs the risk.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Patients should be reviewed regularly while on therapy for any signs or symptoms that might represent myopathy.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Any&nbsp;patient&nbsp;that&nbsp;develops&nbsp;unexplained&nbsp;muscle&nbsp;pain,&nbsp;tenderness,&nbsp;weakness&nbsp;or&nbsp;cramps&nbsp;should have&nbsp;CPK&nbsp;levelsmonitored&nbsp;every&nbsp;2&nbsp;days.&nbsp;Daptomycin&nbsp;TBM&nbsp;should&nbsp;be&nbsp;discontinued&nbsp;in&nbsp;the presence of unexplained muscle symptoms if the CPK level reaches greater than 5 times&nbsp;ULN.</p><p>&nbsp;</p><p><u>Peripheral&nbsp;neuropathy</u></p><p>Patients who develop signs or symptoms that might represent a peripheral neuropathy during therapy with daptomycin should be investigated and consideration should be given to discontinuation of daptomycin (see sections 4.8 and 5.3).</p><p>&nbsp;</p><p><u>Paediatric&nbsp;population</u></p><p>Paediatric patients below the age of one year should not be given daptomycin due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs (see section 5.3).</p><p>&nbsp;</p><p><u>Eosinophilic&nbsp;pneumonia</u></p><p>Eosinophilic pneumonia has been reported in patients receiving daptomycin (see section 4.8). In most reported cases associated with daptomycin, patients developed fever, dyspnoea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organising pneumonia. The majority of cases occurred after more than 2 weeks of treatment with daptomycin and improved&nbsp;when&nbsp;daptomycin&nbsp;was&nbsp;discontinued&nbsp;and&nbsp;steroid&nbsp;therapy&nbsp;was&nbsp;initiated.Recurrence&nbsp;of eosinophilic&nbsp;pneumonia&nbsp;upon&nbsp;re-exposure&nbsp;has&nbsp;been&nbsp;reported.&nbsp;Patients&nbsp;who&nbsp;develop&nbsp;these&nbsp;signs andsymptoms&nbsp;while&nbsp;receiving Daptomycin&nbsp;TBM&nbsp;should&nbsp;undergo&nbsp;prompt&nbsp;medical&nbsp;evaluation, including, if appropriate, bronchoalveolar lavage, to exclude other causes (e.g. bacterial infection, fungal infection, parasites, other medicinal products). Daptomycin&nbsp;TBM should be discontinued immediately and treatment with systemic steroids should be initiated when&nbsp;appropriate.</p><p>&nbsp;</p><p><u>Renal&nbsp;impairment</u></p><p>Renal impairment has been reported during treatment with daptomycin. Severe renal impairment&nbsp;may&nbsp;in&nbsp;itself&nbsp;alsopredispose&nbsp;to&nbsp;elevations&nbsp;in&nbsp;daptomycin&nbsp;levels&nbsp;which&nbsp;may&nbsp;increase the risk of development of myopathy (see above).</p><p>An adjustment of daptomycin dose interval is needed for adult patients whose creatinine clearance&nbsp;is&nbsp;&lt;&nbsp;30&nbsp;ml/min(see&nbsp;sections&nbsp;4.2&nbsp;and&nbsp;5.2).&nbsp;The&nbsp;safety&nbsp;and&nbsp;efficacy&nbsp;of&nbsp;the&nbsp;dose&nbsp;interval adjustment have not been evaluated in controlled clinical trials and the recommendation is mainly based on pharmacokinetic modelling data. DaptomycinTBM should only be used in such patients when it is considered that the expected clinical benefit outweighs the potential&nbsp;risk.</p><p>Caution is advised when administering Daptomycin&nbsp;TBM to patients who already have some degree of renal impairment (creatinine clearance &lt; 80 ml/min) before commencing therapy with&nbsp;Daptomycin&nbsp;TBM.&nbsp;Regularmonitoring&nbsp;of&nbsp;renal&nbsp;function&nbsp;is&nbsp;advised&nbsp;(see&nbsp;also&nbsp;section&nbsp;5.2). In&nbsp;addition,&nbsp;regular&nbsp;monitoring&nbsp;of&nbsp;renal&nbsp;function&nbsp;isadvised&nbsp;during&nbsp;concomitant&nbsp;administration of potentially nephrotoxic agents, regardless of the patient&#39;s pre-existing renal function (see also section 4.5).</p><p>The&nbsp;dosage regimen for daptomycin in&nbsp;paediatric patients&nbsp;with&nbsp;renal&nbsp;impairment&nbsp;has&nbsp;not&nbsp;been&nbsp;established.</p><p>&nbsp;</p><p><u>Obesity</u></p><p>In&nbsp;obese&nbsp;subjects&nbsp;with&nbsp;Body&nbsp;Mass&nbsp;Index&nbsp;(BMI)&nbsp;&gt;&nbsp;40&nbsp;kg/m<sup>2</sup>&nbsp;but&nbsp;with&nbsp;creatinine&nbsp;clearance&gt;70&nbsp;ml/min,&nbsp;the&nbsp;AUC0-&infin;&nbsp;daptomycin&nbsp;was&nbsp;significantly&nbsp;increased&nbsp;(mean&nbsp;42%&nbsp;higher)&nbsp;compared&nbsp;with non-obese matched controls. There is limited information on the safety and efficacy of daptomycin in the very obese and so caution is recommended. However, there is currently no evidence that a dose reduction is required (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin undergoes little to no Cytochrome P450 (CYP450)-mediated metabolism. It is unlikely that daptomycin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.</p><p>Interaction studies for daptomycin were&nbsp;performed with aztreonam, tobramycin, warfarin and probenecid.Daptomycin&nbsp;had&nbsp;no&nbsp;effect&nbsp;on&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;warfarin&nbsp;or&nbsp;probenecid,&nbsp;nor did&nbsp;these&nbsp;medicinal&nbsp;products&nbsp;alterthe&nbsp;pharmacokinetics&nbsp;of&nbsp;daptomycin.&nbsp;The&nbsp;pharmacokinetics of daptomycin were not significantly altered by aztreonam.</p><p>Although&nbsp;small&nbsp;changes&nbsp;in&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;daptomycin&nbsp;and&nbsp;tobramycin&nbsp;were&nbsp;observed during coadministration by intravenous infusion over a 30-minute period using a daptomycin dose of 2&nbsp;mg/kg, the changes were not statistically significant. The interaction between daptomycin and tobramycin with an approved dose of daptomycin is unknown. Caution is warranted when daptomycin is co-administered with tobramycin. Experience with the concomitant&nbsp;administration&nbsp;of&nbsp;daptomycin&nbsp;and&nbsp;warfarin&nbsp;is&nbsp;limited.&nbsp;Studies&nbsp;of&nbsp;daptomycin&nbsp;with anticoagulants&nbsp;other&nbsp;than&nbsp;warfarin&nbsp;have&nbsp;not&nbsp;been&nbsp;conducted.&nbsp;Anticoagulant&nbsp;activity&nbsp;in&nbsp;patients receiving&nbsp;daptomycinand&nbsp;warfarin&nbsp;should&nbsp;be&nbsp;monitored&nbsp;for&nbsp;the&nbsp;first&nbsp;several&nbsp;days&nbsp;after&nbsp;therapy with daptomycin is initiated.</p><p>There is limited experience regarding concomitant administration of daptomycin with other medicinal&nbsp;products&nbsp;thatmay&nbsp;trigger&nbsp;myopathy&nbsp;(e.g.&nbsp;HMG-CoA&nbsp;reductase&nbsp;inhibitors).&nbsp;However, some cases of marked rises in CPK levels and cases of rhabdomyolysis occurred in adult patients taking one of these medicinal products at the same time as daptomycin. It is recommended that other medicinal products associated with myopathy should if possible be temporarily&nbsp;discontinued&nbsp;during&nbsp;treatment&nbsp;with&nbsp;daptomycin&nbsp;unless&nbsp;the&nbsp;benefits&nbsp;of&nbsp;concomitant administration outweigh the risk. If co-administration cannot be avoided, CPK levels should be measured more frequently than once weekly and patients should be closely monitored for any signs or symptoms that might represent myopathy. See sections 4.4, 4.8 and 5.3.</p><p>Daptomycin is primarily cleared by renal filtration and so plasma levels may be increased during&nbsp;co-administrationwith&nbsp;medicinal&nbsp;products&nbsp;that&nbsp;reduce&nbsp;renal&nbsp;filtration&nbsp;(e.g.&nbsp;NSAIDs&nbsp;and COX-2&nbsp;inhibitors).&nbsp;In&nbsp;addition,&nbsp;there&nbsp;is&nbsp;apotential&nbsp;for&nbsp;a&nbsp;pharmacodynamic&nbsp;interaction&nbsp;to&nbsp;occur during co-administration due to additive renal effects. Therefore, caution is advised when daptomycin is co-administered with any other medicinal product known to reduce renal&nbsp;filtration.</p><p>During post&ndash;marketing surveillance, cases of&nbsp;interference&nbsp;between daptomycin and particular reagents used in some assays of prothrombin time/international normalised ratio (PT/INR) have been reported. This interference led to a false prolongation of PT and elevation of INR. If unexplained abnormalities of PT/INR are observed in patients taking daptomycin, consideration should be given to a possible&nbsp;<em>in vitro&nbsp;</em>interaction with the laboratory test. The possibility of erroneous results may be minimised by drawing samples for PT or INR testing near the time of trough plasma concentrations of daptomycin (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No clinical data on pregnancies are available for daptomycin. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>Daptomycin&nbsp;TBM should not be used during pregnancy unless clearly necessary i.e., only if the expected benefit outweighs the possible risk.</p><p><u>Breast-feeding</u></p><p>In&nbsp;a&nbsp;single&nbsp;human&nbsp;case&nbsp;study,&nbsp;daptomycin&nbsp;was&nbsp;intravenously&nbsp;administered&nbsp;daily&nbsp;for&nbsp;28&nbsp;days&nbsp;to a nursing mother at a dose of 500 mg/day, and samples of the patient&#39;s breast milk were collected&nbsp;over&nbsp;a&nbsp;24-hour&nbsp;period&nbsp;on&nbsp;day&nbsp;27.&nbsp;Thehighest&nbsp;measured&nbsp;concentration&nbsp;of&nbsp;daptomycin in the breast milk was 0.045 mcg/ml, which is a low concentration. Therefore, until more experience is gained, breast-feeding should be discontinued when Daptomycin&nbsp;TBM is administered to nursing women.</p><p><u>Fertility</u></p><p>No&nbsp;clinical&nbsp;data&nbsp;on&nbsp;fertility&nbsp;are&nbsp;available&nbsp;for&nbsp;daptomycin.&nbsp;Animal&nbsp;studies&nbsp;do&nbsp;not&nbsp;indicate&nbsp;direct or indirect harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No&nbsp;studies&nbsp;on&nbsp;the&nbsp;effects&nbsp;on&nbsp;the&nbsp;ability&nbsp;to&nbsp;drive&nbsp;and&nbsp;use&nbsp;machines&nbsp;have&nbsp;been&nbsp;performed.</p><p>On&nbsp;the&nbsp;basis&nbsp;of&nbsp;reported&nbsp;adverse drug&nbsp;reactions,&nbsp;Daptomycin&nbsp;is&nbsp;presumed&nbsp;to&nbsp;be&nbsp;unlikely&nbsp;to produce an effect on the ability to drive or use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary&nbsp;of&nbsp;the&nbsp;safety&nbsp;profile</u></p><p>In&nbsp;clinical&nbsp;studies,&nbsp;2,011&nbsp;adult&nbsp;subjects&nbsp;received&nbsp;daptomycin.&nbsp;Within&nbsp;these&nbsp;trials,&nbsp;1,221&nbsp;subjects received a daily dose of 4 mg/kg, of whom 1,108 were patients and 113 were healthy volunteers;&nbsp;460&nbsp;subjects&nbsp;received&nbsp;a&nbsp;daily&nbsp;dose&nbsp;of&nbsp;6mg/kg,&nbsp;of&nbsp;whom&nbsp;304&nbsp;were&nbsp;patients&nbsp;and&nbsp;156 were&nbsp;healthy volunteers. In paediatric studies, 372 patients received daptomycin, of whom 61 received a single dose and 311 received a therapeutic regimen for cSSTI or SAB (daily doses ranged&nbsp;from&nbsp;4&nbsp;mg/kg&nbsp;to&nbsp;12&nbsp;mg/kg).&nbsp;Adverse&nbsp;reactions&nbsp;(i.e.&nbsp;considered&nbsp;by&nbsp;the&nbsp;investigator&nbsp;to&nbsp;be possibly, probably, or definitely related to the medicinal product) were reported at similar frequencies for daptomycin and comparator regimens.</p><p>The most frequently reported adverse reactions [frequency common (&ge; 1/100 to &lt; 1/10)] are: Fungal infections, urinary tract infection, candida infection, anaemia, anxiety, insomnia, dizziness, headache, hypertension, hypotension, gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension, liver function tests abnormal (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)), rash, pruritus, limb pain, serum creatine phosphokinase (CPK) increased, infusion site reactions, pyrexia, asthenia.</p><p>Less frequently reported, but more serious, adverse reactions include hypersensitivity reactions, eosinophilic pneumonia (occasionally presenting as organising pneumonia), drug rash with eosinophilia and systemic symptoms (DRESS), angioedema and rhabdomyolysis.</p><p><u>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions</u></p><p>The following adverse reactions were reported during therapy and during follow-up with frequencies&nbsp;correspondingto&nbsp;very&nbsp;common&nbsp;(&ge;&nbsp;1/10);&nbsp;common&nbsp;(&ge;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10);&nbsp;uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data):</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing&nbsp;seriousness</p><p><strong>Table&nbsp;3:&nbsp;Adverse&nbsp;reactions&nbsp;from&nbsp;clinical&nbsp;studies&nbsp;and&nbsp;post-marketing&nbsp;reports</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System&nbsp;organ&nbsp;class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse&nbsp;reactions</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Fungal&nbsp;&nbsp;&nbsp;&nbsp;infections,&nbsp;&nbsp;&nbsp;&nbsp;urinary&nbsp;&nbsp;&nbsp;&nbsp;tract&nbsp;&nbsp;&nbsp;&nbsp;infection,</p><p>candida&nbsp;infection</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Fungaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known*:</em></p></td><td style="vertical-align:top"><p><em>Clostridium&nbsp;difficile-</em>associated&nbsp;diarrhoea**</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Thrombocythaemia,&nbsp;eosinophilia,&nbsp;international</p><p>normalised&nbsp;ratio&nbsp;(INR)&nbsp;increased,&nbsp;leukocytosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>Prothrombin&nbsp;time&nbsp;(PT)&nbsp;prolonged</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known*:</em></p></td><td style="vertical-align:top"><p>Thrombocytopaenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Not&nbsp;known*:</em></p></td><td style="vertical-align:top"><p>Hypersensitivity**, manifested by isolated spontaneous&nbsp;reports&nbsp;including,&nbsp;but&nbsp;not&nbsp;limitedto angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), pulmonary eosinophilia, vesicobullous rash with mucous membrane involvement and sensation of oropharyngeal&nbsp;swelling,&nbsp;anaphylaxis**,infusion reactions including the following symptoms: tachycardia,&nbsp;wheezing,&nbsp;pyrexia,rigors,&nbsp;systemic</p><p>flushing,&nbsp;vertigo,&nbsp;syncope&nbsp;and&nbsp;metallic&nbsp;taste</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System&nbsp;organ&nbsp;class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nutrition</p><p>disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Decreased&nbsp;appetite,&nbsp;hyperglycaemia,&nbsp;electrolyte</p><p>imbalance</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Anxiety,&nbsp;insomnia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Dizziness,&nbsp;headache</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Paraesthesia,&nbsp;taste&nbsp;disorder,&nbsp;tremor,&nbsp;eye&nbsp;irritation</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known*:</em></p></td><td style="vertical-align:top"><p>Peripheral&nbsp;neuropathy**</p></td></tr><tr><td style="vertical-align:top"><p>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Supraventricular&nbsp;tachycardia,&nbsp;extrasystole</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Hypertension,&nbsp;hypotension</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Flushes</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and</p><p>mediastinal&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Not&nbsp;known*:</em></p></td><td style="vertical-align:top"><p>Eosinophilic&nbsp;pneumonia<sup>1</sup>**,&nbsp;cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Gastrointestinal&nbsp;and&nbsp;abdominal&nbsp;pain,&nbsp;nausea,</p><p>vomiting,&nbsp;constipation,&nbsp;diarrhoea,&nbsp;flatulence, bloating and distension</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Dyspepsia,&nbsp;glossitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Liver&nbsp;function&nbsp;tests&nbsp;abnormal<sup>2</sup>&nbsp;[increasedalanine&nbsp;aminotransferase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ALT),&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aspartate&nbsp;aminotransferase&nbsp;(AST)&nbsp;or alkalinephosphatase</p><p>(ALP)]</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Rash,&nbsp;pruritus</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known*:</em></p></td><td style="vertical-align:top"><p>Acute&nbsp;generalised&nbsp;exanthematous&nbsp;pustulosis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal&nbsp;and&nbsp;connective tissue disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Limb&nbsp;&nbsp;&nbsp;&nbsp;pain,&nbsp;&nbsp;&nbsp;&nbsp;serum&nbsp;&nbsp;&nbsp;&nbsp;creatine&nbsp;&nbsp;&nbsp;&nbsp;phosphokinase</p><p>(CPK)<sup>2</sup>&nbsp;increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Myositis,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;increased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;myoglobin,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;muscular&nbsp;weakness,&nbsp;muscle&nbsp;pain,&nbsp;arthralgia,serum&nbsp;lactate</p><p>dehydrogenase&nbsp;(LDH)&nbsp;increased,&nbsp;muscle&nbsp;cramps</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known*:</em></p></td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>3</sup>**</p></td></tr><tr><td style="vertical-align:top"><p>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Renal&nbsp;impairment,&nbsp;including&nbsp;renal&nbsp;failure&nbsp;and</p><p>renal&nbsp;insufficiency,&nbsp;serum&nbsp;creatinine&nbsp;increased</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive&nbsp;system&nbsp;and&nbsp;breast</p><p>disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Vaginitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and</p><p>administration&nbsp;site&nbsp;conditions</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Infusion&nbsp;site&nbsp;reactions,&nbsp;pyrexia,&nbsp;asthenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Fatigue,&nbsp;pain</p></td></tr></tbody></table><p>&nbsp;</p><p>* Based on post-marketing&nbsp;reports. Since these&nbsp;reactions are&nbsp;reported voluntarily&nbsp;from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.;</p><p>**&nbsp;See&nbsp;section&nbsp;4.4.</p><p>1: While the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate of spontaneous reports is very low (&lt; 1/10,000).</p><p>2:&nbsp;In&nbsp;some&nbsp;cases&nbsp;of&nbsp;myopathy&nbsp;involving&nbsp;raised&nbsp;CPK&nbsp;and&nbsp;muscle&nbsp;symptoms,&nbsp;the&nbsp;patients&nbsp;also&nbsp;presented with elevated transaminases. These transaminase increases were likely to be related to the skeletal muscle effects. The majority of transaminase elevations were of Grade 1-3 toxicity and resolved upon discontinuation of treatment.</p><p>3:&nbsp;When&nbsp;clinical&nbsp;information&nbsp;on&nbsp;the&nbsp;patients&nbsp;was&nbsp;available&nbsp;to&nbsp;make&nbsp;a&nbsp;judgement,&nbsp;approximately&nbsp;50%&nbsp;of the cases occurred in patients with pre-existing renal impairment, or in those receiving concomitant medicinal products known to cause rhabdomyolysis.</p><p>The safety data for the administration of daptomycin via 2-minute intravenous injection are derived from two pharmacokinetic studies in healthy adult volunteers. Based on these study results,&nbsp;both&nbsp;methods&nbsp;of&nbsp;daptomycinadministration,&nbsp;the&nbsp;2-minute&nbsp;intravenous&nbsp;injection&nbsp;and&nbsp;the 30-minute intravenous infusion, had a similar safety and tolerability profile. There was no relevant difference in local tolerability or in the nature and frequency of adverse reactions.</p><p>To&nbsp;reports&nbsp;any&nbsp;side&nbsp;effect(s):</p><p>Reporting&nbsp;suspected&nbsp;adverse&nbsp;reactions&nbsp;after&nbsp;authorisation&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product&nbsp;is&nbsp;important. It&nbsp;allows&nbsp;continuedmonitoring&nbsp;of&nbsp;the&nbsp;benefit/risk&nbsp;balance&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product.&nbsp;Healthcare professionals&nbsp;are&nbsp;asked&nbsp;to&nbsp;report&nbsp;anysuspected&nbsp;adverse&nbsp;reactions&nbsp;to&nbsp;the&nbsp;competent&nbsp;authority&nbsp;in Saudi Arabia as per details below:</p><p>To&nbsp;report&nbsp;any&nbsp;side&nbsp;effect(s):<!--[if !supportLists]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]--><strong><u>Saudi&nbsp;Arabia</u></strong></p><p>The&nbsp;National&nbsp;Pharmacovigilance&nbsp;and&nbsp;Drug&nbsp;Safety Centre&nbsp;(NPC)</p><p>-&nbsp;&nbsp;&nbsp; Fax:&nbsp;+966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222,&nbsp;Ext&nbsp;2317-2356-2340</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->SFDA&nbsp;Call&nbsp;Center:&nbsp;19999</p><p><!--[if !supportLists]-->- &nbsp; &nbsp;E-mail:&nbsp;npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;Website:&nbsp;https://ade.sfda.gov.sa/</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]--><strong><u>Other&nbsp;GCC&nbsp;States:</u></strong></p><p>- &nbsp; &nbsp;&nbsp;<!--[endif]-->Please&nbsp;contact&nbsp;the&nbsp;relevant&nbsp;competent&nbsp;authority.</p><table cellpadding="0" cellspacing="0" align="left" style="width:382.25px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:437.75px">&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, supportive care is advised. Daptomycin is slowly cleared from the body&nbsp;by&nbsp;haemodialysis(approximately&nbsp;15%&nbsp;of&nbsp;the&nbsp;administered&nbsp;dose&nbsp;is&nbsp;removed&nbsp;over&nbsp;4&nbsp;hours) or by peritoneal dialysis (approximately 11% of the administered dose is removed over 48&nbsp;hours).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;Antibacterials&nbsp;for&nbsp;systemic&nbsp;use,&nbsp;Other&nbsp;antibacterials ATC code: J01XX09</p><p>&nbsp;</p><p><u>Mechanism&nbsp;of&nbsp;action</u></p><p>Daptomycin&nbsp;is&nbsp;a&nbsp;cyclic&nbsp;lipopeptide&nbsp;natural&nbsp;product&nbsp;that&nbsp;is&nbsp;active&nbsp;against&nbsp;Gram&nbsp;positive&nbsp;bacteria only. The&nbsp;mechanism of action involves binding (in the&nbsp;presence&nbsp;of calcium ions) to bacterial membranes&nbsp;of&nbsp;both&nbsp;growing&nbsp;and&nbsp;stationaryphase&nbsp;cells&nbsp;causing&nbsp;depolarisation&nbsp;and&nbsp;leading&nbsp;to&nbsp;a rapid inhibition of protein, DNA, and RNA synthesis. This results in bacterial cell death with negligible cell lysis.</p><p><u>PK/PD&nbsp;relationship</u></p><p>Daptomycin&nbsp;exhibits&nbsp;rapid,&nbsp;concentration&nbsp;dependent&nbsp;bactericidal&nbsp;activity&nbsp;against&nbsp;Gram&nbsp;positive&nbsp;organisms&nbsp;<em>in vitro&nbsp;</em>and in&nbsp;<em>in vivo&nbsp;</em>animal models. In animal models AUC/MIC and Cmax/MIC&nbsp;correlate with efficacy and predicted bacterial kill&nbsp;<em>in vivo&nbsp;</em>at single doses&nbsp;equivalent to human adult doses of 4 mg/kg and 6 mg/kg once daily.</p><p><u>Mechanism&nbsp;of&nbsp;resistance</u></p><p>Strains with decreased susceptibility to daptomycin have been reported especially during the treatment of patients with difficult-to-treat infections and/or following administration for prolonged periods. In particular, there have been reports of treatment failures in patients infected with&nbsp;<em>Staphylococcus aureus, Enterococcus faecalis&nbsp;</em>or&nbsp;<em>Enterococcus faecium</em>, including&nbsp;bacteraemic&nbsp;patients,&nbsp;that&nbsp;have&nbsp;been&nbsp;associated&nbsp;with&nbsp;the&nbsp;selection&nbsp;of&nbsp;organismswith reduced susceptibility or frank resistance to daptomycin during therapy.</p><p>The&nbsp;mechanism(s)&nbsp;of&nbsp;daptomycin&nbsp;resistance&nbsp;is&nbsp;(are)&nbsp;not&nbsp;fully&nbsp;understood.</p><p><u>Breakpoints</u></p><p>Minimum inhibitory concentration (MIC) breakpoint established by the European Committee on&nbsp;AntimicrobialSusceptibility&nbsp;Testing&nbsp;(EUCAST)&nbsp;for&nbsp;<em>Staphylococci&nbsp;</em>and&nbsp;<em>Streptococci&nbsp;</em>(except</p><p><em>S.&nbsp;pneumoniae</em>) are&nbsp;Susceptible &le;&nbsp;1&nbsp;mg/L&nbsp;and Resistant&nbsp;&gt;&nbsp;1&nbsp;mg/L.</p><p><u>Susceptibility</u></p><p>The prevalence of resistance may vary geographically and over time for selected species and local&nbsp;information&nbsp;onresistance&nbsp;is&nbsp;desirable,&nbsp;particularly&nbsp;when&nbsp;treating&nbsp;severe&nbsp;infections.&nbsp;As&nbsp;necessary,&nbsp;expert&nbsp;advice should be&nbsp;sought when the&nbsp;local prevalence&nbsp;of resistance&nbsp;is such that the utility of the agent in at least some types of infections is questionable.</p><p><strong>Table&nbsp;4:&nbsp;List&nbsp;of&nbsp;susceptible&nbsp;species</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly&nbsp;Susceptible&nbsp;Species</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus&nbsp;aureus</em>*</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus&nbsp;haemolyticus</em></p></td></tr><tr><td style="vertical-align:top"><p>Coagulase&nbsp;negative&nbsp;staphylococci</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;agalactiae</em>*</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;dysgalactiae&nbsp;subsp&nbsp;equisimilis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;pyogenes</em>*</p></td></tr><tr><td style="vertical-align:top"><p>Group&nbsp;G&nbsp;streptococci</p></td></tr><tr><td style="vertical-align:top"><p><em>Clostridium&nbsp;perfringens</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Peptostreptococcus&nbsp;spp</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently&nbsp;resistant&nbsp;organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gram&nbsp;negative&nbsp;organisms</p></td></tr></tbody></table><p>* denotes species against which it is considered that activity has been satisfactorily demonstrated in clinical studies.</p><p>&nbsp;</p><p><u>Clinical&nbsp;efficacy&nbsp;in&nbsp;adults</u></p><p>In two adult clinical trials in complicated skin and soft tissues infections, 36% of patients treated&nbsp;with&nbsp;daptomycinmet&nbsp;the&nbsp;criteria&nbsp;for&nbsp;systemic&nbsp;inflammatory&nbsp;response&nbsp;syndrome&nbsp;(SIRS). The&nbsp;most&nbsp;common&nbsp;type&nbsp;of&nbsp;infection&nbsp;treatedwas&nbsp;wound&nbsp;infection&nbsp;(38%&nbsp;of&nbsp;patients),&nbsp;while&nbsp;21% had major abscesses. These limitations of the patients population treated should be taken into account when deciding to use daptomycin.</p><p>In a&nbsp;randomised controlled&nbsp;open-label&nbsp;study&nbsp;in&nbsp;235&nbsp;adult&nbsp;patients&nbsp;with&nbsp;<em>Staphylococcus&nbsp;aureus&nbsp;</em>bacteraemia&nbsp;(i.e.&nbsp;atleast&nbsp;one&nbsp;positive&nbsp;blood&nbsp;culture&nbsp;of&nbsp;<em>Staphylococcus&nbsp;aureus&nbsp;</em>prior&nbsp;to&nbsp;receiving the&nbsp;first&nbsp;dose)&nbsp;19&nbsp;of&nbsp;120 patients&nbsp;treatedwith&nbsp;daptomycin&nbsp;met&nbsp;the&nbsp;criteria&nbsp;for&nbsp;RIE.&nbsp;Of&nbsp;these&nbsp;19 patients 11 were infected with methicillin-susceptible and 8 with methicillin resistant&nbsp;<em>Staphylococcus aureus</em>. The success rates in RIE patients are shown in the table 5 below.</p><p><strong>Table&nbsp;5:&nbsp;The&nbsp;success&nbsp;rates&nbsp;in&nbsp;RIE&nbsp;patients</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Population</strong></p></td><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td><td style="vertical-align:top"><p><strong>Differences&nbsp;in</strong></p><p><strong>Success</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>n/N&nbsp;(%)</strong></p></td><td style="vertical-align:top"><p><strong>n/N&nbsp;(%)</strong></p></td><td style="vertical-align:top"><p><strong>Rates&nbsp;(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ITT&nbsp;(intention&nbsp;to&nbsp;treat)&nbsp;Population</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RIE</p></td><td style="vertical-align:top"><p>8/19&nbsp;(42.1%)</p></td><td style="vertical-align:top"><p>7/16&nbsp;(43.8%)</p></td><td style="vertical-align:top"><p>-1.6%&nbsp;(-34.6,31.3)</p></td></tr><tr><td style="vertical-align:top"><p>PP&nbsp;(per&nbsp;protocol)&nbsp;Population</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RIE</p></td><td style="vertical-align:top"><p>6/12&nbsp;(50.0%)</p></td><td style="vertical-align:top"><p>4/8&nbsp;(50.0%)</p></td><td style="vertical-align:top"><p>0.0%&nbsp;(-44.7,&nbsp;44.7)</p></td></tr></tbody></table><p>Failure of treatment due to persisting or relapsing&nbsp;<em>Staphylococcus aureus&nbsp;</em>infections was observed in 19/120 (15.8%) patients treated with daptomycin, 9/53 (16.7%) patients treated with vancomycin and 2/62 (3.2%) patients treated with an anti-staphylococcal semi-synthetic penicillin. Among these failures six patients treated with daptomycin and one patient treated with vancomycin were infected with&nbsp;<em>Staphylococcus aureus&nbsp;</em>that developed increasing MICs of&nbsp;daptomycin&nbsp;on&nbsp;or&nbsp;following&nbsp;therapy&nbsp;(see&nbsp;&ldquo;Mechanisms&nbsp;of&nbsp;resistance&rdquo;&nbsp;above).&nbsp;Most&nbsp;patients who failed due to persisting or relapsing&nbsp;<em>Staphylococcus aureus&nbsp;</em>infection had deep-seated infection and did not receive necessary surgical intervention.</p><p><u>Clinical&nbsp;efficacy&nbsp;in&nbsp;paediatric&nbsp;patients</u></p><p>The&nbsp;safety and efficacy of&nbsp;daptomycin was evaluated&nbsp;in paediatric&nbsp;patients aged 1 to 17 years with&nbsp;cSSTI&nbsp;caused&nbsp;byGram&nbsp;positive&nbsp;pathogens.&nbsp;Patients&nbsp;were&nbsp;enrolled&nbsp;in&nbsp;a&nbsp;stepwise&nbsp;approach into well-defined age groups and given age-dependent doses once daily for up to 14 days, as&nbsp;follows:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Age&nbsp;group&nbsp;1&nbsp;(n=113):&nbsp;12&nbsp;to&nbsp;17&nbsp;years&nbsp;treated&nbsp;with&nbsp;daptomycin&nbsp;dosed&nbsp;at&nbsp;5&nbsp;mg/kg&nbsp;or&nbsp;standard- of-care comparator (SOC);</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Age&nbsp;group 2&nbsp;(n=113): 7&nbsp;to 11&nbsp;years treated with&nbsp;daptomycin dosed&nbsp;at 7&nbsp;mg/kg or&nbsp;SOC;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Age&nbsp;group 3&nbsp;(n=125): 2&nbsp;to&nbsp;6&nbsp;years treated with&nbsp;daptomycin dosed&nbsp;at 9&nbsp;mg/kg or&nbsp;SOC;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Age group 4 (n=45): 1 to &lt; 2 years treated with daptomycin dosed at 10 mg/kg or SOC The&nbsp;primary&nbsp;objective&nbsp;ofthis&nbsp;study&nbsp;was&nbsp;to&nbsp;assess&nbsp;the&nbsp;safety&nbsp;of&nbsp;treatment.&nbsp;Secondary&nbsp;objectives included&nbsp;an&nbsp;assessment&nbsp;of&nbsp;efficacy&nbsp;of&nbsp;age-dependent&nbsp;doses&nbsp;of&nbsp;intravenous&nbsp;daptomycin&nbsp;in comparison&nbsp;with&nbsp;standard-of-care&nbsp;therapy.&nbsp;The&nbsp;key&nbsp;efficacyendpoint&nbsp;was&nbsp;the&nbsp;sponsor-defined clinical outcome at test-of-cure (TOC), which was defined by a blinded medical director. A&nbsp;total&nbsp;of&nbsp;389&nbsp;subjects&nbsp;were&nbsp;treated&nbsp;in&nbsp;the&nbsp;study,&nbsp;including&nbsp;256&nbsp;subjects&nbsp;who&nbsp;received&nbsp;daptomycin and 133 subjects who received standard-of-care. In all populations the clinical success rates were comparable between the daptomycin and SOC treatment arms, supporting the primary efficacy analysis in the ITT population.</p><p><strong>Table&nbsp;6:&nbsp;Summary&nbsp;of&nbsp;sponsor-defined&nbsp;clinical&nbsp;outcome&nbsp;at&nbsp;TOC:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Clinical&nbsp;success&nbsp;in&nbsp;Paediatric&nbsp;cSSTI</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>%&nbsp;difference</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p><p><strong>n/N&nbsp;(%)</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p><p><strong>n/N&nbsp;(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Intent-to-treat</p></td><td style="vertical-align:top"><p>227/257&nbsp;(88.3%)</p></td><td style="vertical-align:top"><p>114/132&nbsp;(86.4%)</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Modified&nbsp;intent-to-treat</p></td><td style="vertical-align:top"><p>186/210&nbsp;(88.6%)</p></td><td style="vertical-align:top"><p>92/105&nbsp;(87.6%)</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Clinically&nbsp;evaluable</p></td><td style="vertical-align:top"><p>204/207&nbsp;(98.6%)</p></td><td style="vertical-align:top"><p>99/99&nbsp;(100%)</p></td><td style="vertical-align:top"><p>-1.5</p></td></tr><tr><td style="vertical-align:top"><p>Microbiologically&nbsp;evaluable&nbsp;(ME)</p></td><td style="vertical-align:top"><p>164/167&nbsp;(98.2%)</p></td><td style="vertical-align:top"><p>78/78&nbsp;(100%)</p></td><td style="vertical-align:top"><p>-1.8</p></td></tr></tbody></table><p>The overall therapeutic response rate also was similar for the daptomycin and SOC treatment arms for infections caused by MRSA, MSSA and Streptococcus pyogenes (see table 7; ME population); response rates were &gt; 94% for both treatment arms across these common&nbsp;pathogens.</p><p><strong>Table 7: Summary of overall therapeutic response by type of baseline pathogen (ME&nbsp;population):</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Overall&nbsp;Success<sup>a</sup>&nbsp;rate&nbsp;in&nbsp;Paediatric&nbsp;cSSTI</strong></p><p><strong>n/N&nbsp;(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-susceptible&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Staphylococcus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aureus</em></p><p>(MSSA)</p></td><td style="vertical-align:top"><p>68/69&nbsp;(99%)</p></td><td style="vertical-align:top"><p>28/29&nbsp;(97%)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Staphylococcus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aureus</em></p><p>(MRSA)</p></td><td style="vertical-align:top"><p>63/66&nbsp;(96%)</p></td><td style="vertical-align:top"><p>34/34&nbsp;(100%)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;pyogenes</em></p></td><td style="vertical-align:top"><p>17/18&nbsp;(94%)</p></td><td style="vertical-align:top"><p>5/5&nbsp;(100%)</p></td></tr></tbody></table><p>a:&nbsp;Subjects&nbsp;achieving&nbsp;clinical&nbsp;success&nbsp;(Clinical&nbsp;Response&nbsp;of&nbsp;&ldquo;Cure&rdquo;&nbsp;or&nbsp;&ldquo;Improved&rdquo;)&nbsp;and&nbsp;microbiological success (pathogen&ndash;level response of &ldquo;Eradicated&rdquo; or &ldquo;Presumed Eradicated&rdquo;) are classified as overall therapeutic success</p><p>The&nbsp;safety and efficacy of&nbsp;daptomycin was evaluated&nbsp;in paediatric&nbsp;patients aged 1 to 17 years (Study DAP-PEDBAC-11-02) with bacteraemia caused by&nbsp;<em>Staphylococcus aureus</em>. Patients were randomised in a 2:1 ratio into the following age groups and given age-dependent doses once daily for up to 42 days, as follows:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Age&nbsp;group&nbsp;1&nbsp;(n=21):&nbsp;12&nbsp;to&nbsp;17&nbsp;years&nbsp;treated&nbsp;with&nbsp;daptomycin&nbsp;dosed&nbsp;at&nbsp;7&nbsp;mg/kg&nbsp;or&nbsp;SOC&nbsp;comparator;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Age&nbsp;group&nbsp;2 (n=28):&nbsp;7 to&nbsp;11 years&nbsp;treated&nbsp;with daptomycin&nbsp;dosed at&nbsp;9 mg/kg&nbsp;or&nbsp;SOC;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Age&nbsp;group 3&nbsp;(n=32): 1&nbsp;to&nbsp;6&nbsp;years treated&nbsp;with daptomycin&nbsp;dosed at&nbsp;12 mg/kg&nbsp;or&nbsp;SOC;</p><p>&nbsp;</p><p>The primary objective of Study DAP-PEDBAC-11-02 was to assess the safety of intravenous daptomycin&nbsp;versusSOC&nbsp;antibiotics.&nbsp;Secondary&nbsp;objectives&nbsp;included:&nbsp;Clinical&nbsp;outcome&nbsp;based&nbsp;on the blinded Evaluator&#39;s assessment of clinical response (success [cure, improved], failure, or non-evaluable) at the TOC Visit; and Microbiological response (success, failure, or non- evaluable) based on evaluation of Baseline infecting pathogen at TOC.</p><p>A&nbsp;total&nbsp;of&nbsp;81&nbsp;subjects&nbsp;were&nbsp;treated&nbsp;in&nbsp;the&nbsp;study,&nbsp;including&nbsp;55&nbsp;subjects&nbsp;who&nbsp;received&nbsp;daptomycin and&nbsp;26&nbsp;subjects&nbsp;who received&nbsp;standard-of-care.&nbsp;No&nbsp;patients&nbsp;1&nbsp;to &lt;2&nbsp;years&nbsp;of&nbsp;age&nbsp;were&nbsp;enrolled in the study. In all populations the clinical success rates were comparable in the daptomycin versus the SOC treatment arm.</p><p><strong>Table&nbsp;8:&nbsp;Summary&nbsp;of&nbsp;Blinded&nbsp;Evaluator&nbsp;defined&nbsp;clinical&nbsp;outcome&nbsp;at&nbsp;TOC:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Clinical&nbsp;Success&nbsp;in&nbsp;Paediatric&nbsp;SAB</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>%&nbsp;difference</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p><p><strong>n/N&nbsp;(%)</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p><p><strong>n/N&nbsp;(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Modified&nbsp;intent-to-treat&nbsp;(MITT)</p></td><td style="vertical-align:top"><p>46/52&nbsp;(88.5%)</p></td><td style="vertical-align:top"><p>19/24&nbsp;(79.2%)</p></td><td style="vertical-align:top"><p>9.3%</p></td></tr><tr><td style="vertical-align:top"><p>Microbiologically&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;modified</p><p>intent-to-treat&nbsp;(mMITT)</p></td><td style="vertical-align:top"><p>45/51&nbsp;(88.2%)</p></td><td style="vertical-align:top"><p>17/22&nbsp;(77.3%)</p></td><td style="vertical-align:top"><p>11.0%</p></td></tr><tr><td style="vertical-align:top"><p>Clinically&nbsp;evaluable&nbsp;(CE)</p></td><td style="vertical-align:top"><p>36/40&nbsp;(90.0%)</p></td><td style="vertical-align:top"><p>9/12&nbsp;(75.0%)</p></td><td style="vertical-align:top"><p>15.0%</p></td></tr></tbody></table><p>The microbiological outcome at TOC for the daptomycin and SOC treatment arms for infections caused by MRSA and MSSA are presented in the table 9 (mMITT population).</p><p><strong>Table&nbsp;9:&nbsp;Microbiological&nbsp;outcome&nbsp;at&nbsp;TOC</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Microbiological&nbsp;Success<sup>a</sup>&nbsp;rate&nbsp;in Paediatric SAB</strong></p><p><strong>n/N&nbsp;(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-susceptible&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Staphylococcus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aureus</em></p><p>(MSSA)</p></td><td style="vertical-align:top"><p>43/44&nbsp;(97.7%)</p></td><td style="vertical-align:top"><p>19/19&nbsp;(100.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Staphylococcus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aureus</em></p><p>(MRSA)</p></td><td style="vertical-align:top"><p>6/7&nbsp;(85.7%)</p></td><td style="vertical-align:top"><p>3/3&nbsp;(100.0%)</p></td></tr></tbody></table><p>​​​​​​​</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin&nbsp;pharmacokinetics&nbsp;are&nbsp;generally&nbsp;linear&nbsp;and&nbsp;time-independent&nbsp;at&nbsp;doses&nbsp;of&nbsp;4&nbsp;to 12&nbsp;mg/kgadministered&nbsp;as&nbsp;a&nbsp;single&nbsp;daily&nbsp;dose&nbsp;by&nbsp;30-minute&nbsp;intravenous&nbsp;infusion&nbsp;for&nbsp;up&nbsp;to 14&nbsp;days&nbsp;in&nbsp;healthy&nbsp;adultvolunteers.&nbsp;Steady-state&nbsp;concentrations&nbsp;are&nbsp;achieved&nbsp;by&nbsp;the&nbsp;third&nbsp;daily&nbsp;dose.</p><p>Daptomycin&nbsp;administered&nbsp;as&nbsp;a&nbsp;2-minute&nbsp;intravenous&nbsp;injection&nbsp;also&nbsp;exhibited&nbsp;dose&nbsp;proportional pharmacokinetics in the approved therapeutic dose range of 4 to 6 mg/kg. Comparable&nbsp;exposure&nbsp;(AUC&nbsp;and&nbsp;Cmax)&nbsp;was&nbsp;demonstrated&nbsp;inhealthy&nbsp;adult&nbsp;subjects&nbsp;following&nbsp;administration&nbsp;of daptomycin as a 30-minute intravenous infusion or as a 2-minute intravenous injection.</p><p>Animal studies showed that daptomycin is not absorbed to any significant extent after oral&nbsp;administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution at steady state of daptomycin in healthy adult subjects was approximately&nbsp;0.1&nbsp;L/kg&nbsp;andwas&nbsp;independent&nbsp;of&nbsp;dose.&nbsp;Tissue&nbsp;distribution&nbsp;studies&nbsp;in&nbsp;rats&nbsp;showed that daptomycin appears to only minimally penetrate&nbsp;the blood-brain barrier&nbsp;and the&nbsp;placental barrier following single and multiple doses.</p><p>Daptomycin is reversibly bound to human plasma proteins in a concentration independent manner.&nbsp;In&nbsp;healthy&nbsp;adultvolunteers&nbsp;and&nbsp;adult&nbsp;patients&nbsp;treated&nbsp;with&nbsp;daptomycin,&nbsp;protein&nbsp;binding averaged about 90% including subjects with renal impairment.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>In&nbsp;<em>in vitro&nbsp;</em>studies, daptomycin was not metabolised by human liver microsomes.&nbsp;<em>In vitro&nbsp;</em>studies with human hepatocytes indicate that daptomycin does not inhibit or induce the activities&nbsp;of&nbsp;the&nbsp;following&nbsp;human&nbsp;cytochromeP450&nbsp;isoforms:&nbsp;1A2,&nbsp;2A6,&nbsp;2C9,&nbsp;2C19,&nbsp;2D6,&nbsp;2E1 and 3A4. It is unlikely that daptomycin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.</p><p>After&nbsp;infusion&nbsp;of&nbsp;<sup>14</sup>C-daptomycin&nbsp;in&nbsp;healthy&nbsp;adults,&nbsp;the&nbsp;plasma&nbsp;radioactivity&nbsp;was&nbsp;similar&nbsp;to&nbsp;the concentration determined by microbiological assay. Inactive metabolites were detected in urine,&nbsp;as&nbsp;determined&nbsp;by&nbsp;the&nbsp;difference&nbsp;intotal&nbsp;radioactive&nbsp;concentrations&nbsp;and&nbsp;microbiologically active&nbsp;concentrations.&nbsp;In a&nbsp;separate&nbsp;study,&nbsp;no&nbsp;metabolites&nbsp;wereobserved&nbsp;in&nbsp;plasma,&nbsp;and&nbsp;minor amounts&nbsp;of&nbsp;three&nbsp;oxidative&nbsp;metabolites&nbsp;and&nbsp;one&nbsp;unidentified&nbsp;compound&nbsp;were&nbsp;detectedin&nbsp;urine. The site of metabolism has not been identified.</p><p><u>Elimination</u></p><p>Daptomycin is excreted primarily by the kidneys. Concomitant administration of probenecid and&nbsp;daptomycin&nbsp;has&nbsp;noeffect&nbsp;on&nbsp;daptomycin&nbsp;pharmacokinetics&nbsp;in&nbsp;humans&nbsp;suggesting&nbsp;minimal to no active tubular secretion of daptomycin.</p><p>Following intravenous administration, plasma clearance of daptomycin is approximately 7 to 9 ml/h/kg and its renal clearance is 4 to 7 ml/h/kg.</p><p>In a mass balance study using radiolabelled material, 78% of the administered dose was recovered from the urine based on total radioactivity, whilst urinary recovery of unchanged daptomycin&nbsp;was&nbsp;approximately&nbsp;50%&nbsp;of&nbsp;the&nbsp;dose.About&nbsp;5%&nbsp;of&nbsp;the&nbsp;administered&nbsp;radiolabel&nbsp;was excreted in the faeces.</p><p>&nbsp;</p><p><u>Special&nbsp;populations</u></p><p><em>Elderly</em></p><p>Following&nbsp;administration&nbsp;of&nbsp;a&nbsp;single&nbsp;4&nbsp;mg/kg&nbsp;intravenous&nbsp;dose&nbsp;of&nbsp;daptomycin&nbsp;over&nbsp;a&nbsp;30-minute period, the mean total clearance of daptomycin was approximately 35% lower and the mean&nbsp;AUC0-&infin;&nbsp;was approximately 58%&nbsp;higher&nbsp;in elderly subjects (&ge;&nbsp;75 years&nbsp;of&nbsp;age) compared with those&nbsp;in&nbsp;healthy&nbsp;young&nbsp;subjects&nbsp;(18&nbsp;to&nbsp;30&nbsp;years&nbsp;of&nbsp;age).&nbsp;Therewere&nbsp;no&nbsp;differences&nbsp;in&nbsp;Cmax.&nbsp;<br />The&nbsp;differences&nbsp;noted&nbsp;are&nbsp;most&nbsp;likely&nbsp;due&nbsp;to&nbsp;the&nbsp;normal&nbsp;reduction&nbsp;in&nbsp;renal&nbsp;function&nbsp;observed&nbsp;in&nbsp;the geriatric population.<br />No dose adjustment is necessary based on age alone. However, renal function should be assessed and the dose should be reduced if there is evidence of severe renal impairment.</p><p>&nbsp;</p><p><em>Children&nbsp;and&nbsp;adolescents&nbsp;(1&nbsp;to&nbsp;17&nbsp;years&nbsp;of&nbsp;age)</em></p><p>The pharmacokinetics of daptomycin in paediatric subjects was evaluated in 3 single-dose pharmacokinetic&nbsp;studies.After&nbsp;a&nbsp;single&nbsp;4&nbsp;mg/kg&nbsp;dose&nbsp;of&nbsp;daptomycin,&nbsp;total&nbsp;clearance&nbsp;normalised by weight and elimination half-life of daptomycin in adolescents (12-17 years of age) with Gram-positive infection were similar to adults. After a single 4 mg/kg dose of daptomycin, total clearance of daptomycin in children 7-11 years of age with Gram-positive infection was higher than in adolescents, whereas elimination half-life was shorter. After a single 4, 8, or&nbsp;10&nbsp;mg/kg dose of daptomycin, total clearance and elimination half-life of daptomycin in children 2-6 years of age were similar at different doses; total clearance was higher and elimination half-life was shorter than in adolescents. After a single 6 mg/kg dose of daptomycin,&nbsp;the&nbsp;clearance&nbsp;and&nbsp;elimination&nbsp;half-life&nbsp;of&nbsp;daptomycin&nbsp;in&nbsp;children&nbsp;13-24&nbsp;months&nbsp;of age were similar to children 2-6 years of age who received a single 4-10 mg/kg dose. The results of these studies show that exposures (AUC) in paediatric patients across all&nbsp;doses are generally lower than those in adults at comparable doses.</p><p><em>Paediatric&nbsp;patients&nbsp;with&nbsp;cSSTI</em></p><p>A&nbsp;Phase&nbsp;4&nbsp;study&nbsp;was&nbsp;conducted&nbsp;to&nbsp;assess&nbsp;safety,&nbsp;efficacy,&nbsp;and&nbsp;pharmacokinetics&nbsp;of&nbsp;daptomycin in paediatric patients (1 to 17 years old, inclusive) with cSSTI caused by Gram-positive pathogens.&nbsp;Daptomycin&nbsp;pharmacokinetics&nbsp;inpatients&nbsp;in&nbsp;this&nbsp;study&nbsp;are&nbsp;summarised&nbsp;in&nbsp;Table&nbsp;10. Following&nbsp;administration&nbsp;of&nbsp;multiple&nbsp;doses,&nbsp;daptomycin&nbsp;exposurewas&nbsp;similar&nbsp;across&nbsp;different age groups after dose adjustment based on body weight and age.</p><p>Plasma exposures achieved with these doses were consistent with those achieved in the adult cSSTI study (following 4 mg/kg once daily in adults).</p><p><strong>Table 10: Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric cSSTI Patients (1 to 17 Years of Age)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age&nbsp;Range</strong></p></td><td style="vertical-align:top"><p><strong>12-17&nbsp;years</strong></p><p><strong>(N=6)</strong></p></td><td style="vertical-align:top"><p><strong>7-11&nbsp;years</strong></p><p><strong>(N=2)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>2-6&nbsp;years</strong></p><p><strong>(N=7)</strong></p></td><td style="vertical-align:top"><p><strong>1&nbsp;to&nbsp;&lt;2&nbsp;years</strong></p><p><strong>(N=30)<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Dose</p><p>Infusion&nbsp;Time</p></td><td style="vertical-align:top"><p>5&nbsp;mg/kg</p><p>30&nbsp;minutes</p></td><td style="vertical-align:top"><p>7&nbsp;mg/kg</p><p>30&nbsp;minutes</p></td><td style="vertical-align:top"><p>9&nbsp;mg/kg</p><p>60&nbsp;minutes</p></td><td style="vertical-align:top"><p>10&nbsp;mg/kg</p><p>60&nbsp;minutes</p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24hr&nbsp;(&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>387&nbsp;(81)</p></td><td style="vertical-align:top"><p>438</p></td><td style="vertical-align:top"><p>439&nbsp;(102)</p></td><td style="vertical-align:top"><p>466</p></td></tr><tr><td style="vertical-align:top"><p>Cmax&nbsp;(&mu;g/ml)</p></td><td style="vertical-align:top"><p>62.4&nbsp;(10.4)</p></td><td style="vertical-align:top"><p>64.9,&nbsp;74.4</p></td><td style="vertical-align:top"><p>81.9&nbsp;(21.6)</p></td><td style="vertical-align:top"><p>79.2</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age&nbsp;Range</strong></p></td><td style="vertical-align:top"><p><strong>12-17&nbsp;years</strong></p><p><strong>(N=6)</strong></p></td><td style="vertical-align:top"><p><strong>7-11&nbsp;years</strong></p><p><strong>(N=2)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>2-6&nbsp;years</strong></p><p><strong>(N=7)</strong></p></td><td style="vertical-align:top"><p><strong>1&nbsp;to&nbsp;&lt;2&nbsp;years</strong></p><p><strong>(N=30)<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Apparent&nbsp;t1/2&nbsp;(hr)</p></td><td style="vertical-align:top"><p>5.3&nbsp;(1.6)</p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>3.8&nbsp;(0.3)</p></td><td style="vertical-align:top"><p>5.04</p></td></tr><tr><td style="vertical-align:top"><p>CL/wt&nbsp;(ml/hr/kg)</p></td><td style="vertical-align:top"><p>13.3&nbsp;(2.9)</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>21.4&nbsp;(5.0)</p></td><td style="vertical-align:top"><p>21.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Pharmacokinetic&nbsp;parameter&nbsp;values&nbsp;estimated&nbsp;by&nbsp;noncompartmental&nbsp;analysis</p><p>aIndividual&nbsp;values&nbsp;reported&nbsp;as&nbsp;only&nbsp;two&nbsp;patients&nbsp;in&nbsp;this&nbsp;age&nbsp;group&nbsp;provided&nbsp;pharmacokineticsamples&nbsp;to enable&nbsp;pharmacokinetic analysis; AUC, apparent t1/2&nbsp;and CL/wt could be determined for only&nbsp;one of the two patients</p><p>bPharmacokinetic analysis conducted on the pooled pharmacokinetic profile with mean concentrations across subjects at&nbsp;each time point</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Paediatric&nbsp;patients&nbsp;with&nbsp;SAB</em></p><p>A&nbsp;Phase&nbsp;4&nbsp;study&nbsp;was&nbsp;conducted&nbsp;to&nbsp;assess&nbsp;safety,&nbsp;efficacy,&nbsp;and&nbsp;pharmacokinetics&nbsp;of&nbsp;daptomycin in paediatric patients (1 to 17 years old, inclusive) with SAB. Daptomycin pharmacokinetics inpatients&nbsp;in&nbsp;this&nbsp;study&nbsp;are&nbsp;summarised&nbsp;inTable&nbsp;11.&nbsp;Following&nbsp;administration&nbsp;of&nbsp;multiple&nbsp;doses, daptomycin exposure was similar across different age groups after dose adjustment based on body weight and age. Plasma exposures achieved with these doses were&nbsp;consistent with those achieved in the adult SAB study (following 6 mg/kg once daily in adults).</p><p><strong>Table 11: Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric SAB Patients (1 to 17 Years of Age)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Age&nbsp;Range</p></td><td style="vertical-align:top"><p>12-17&nbsp;years(N=13)</p></td><td style="vertical-align:top"><p>7-11&nbsp;years(N=19)</p></td><td style="vertical-align:top"><p>1&nbsp;to 6&nbsp;years(N=19)*</p></td></tr><tr><td style="vertical-align:top"><p>Dose</p><p>Infusion&nbsp;Time</p></td><td style="vertical-align:top"><p>7&nbsp;mg/kg</p><p>30&nbsp;minutes</p></td><td style="vertical-align:top"><p>9&nbsp;mg/kg</p><p>30&nbsp;minutes</p></td><td style="vertical-align:top"><p>12&nbsp;mg/kg</p><p>60&nbsp;minutes</p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24hr&nbsp;(&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>656&nbsp;(334)</p></td><td style="vertical-align:top"><p>579&nbsp;(116)</p></td><td style="vertical-align:top"><p>620&nbsp;(109)</p></td></tr><tr><td style="vertical-align:top"><p>Cmax&nbsp;(&mu;g/ml)</p></td><td style="vertical-align:top"><p>104&nbsp;(35.5)</p></td><td style="vertical-align:top"><p>104&nbsp;(14.5)</p></td><td style="vertical-align:top"><p>106&nbsp;(12.8)</p></td></tr><tr><td style="vertical-align:top"><p>Apparent&nbsp;t1/2&nbsp;(hr)</p></td><td style="vertical-align:top"><p>7.5&nbsp;(2.3)</p></td><td style="vertical-align:top"><p>6.0&nbsp;(0.8)</p></td><td style="vertical-align:top"><p>5.1&nbsp;(0.6)</p></td></tr><tr><td style="vertical-align:top"><p>CL/wt&nbsp;(ml/hr/kg)</p></td><td style="vertical-align:top"><p>12.4&nbsp;(3.9)</p></td><td style="vertical-align:top"><p>15.9&nbsp;(2.8)</p></td><td style="vertical-align:top"><p>19.9&nbsp;(3.4)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Pharmacokinetic parameter values estimated using a model-based approach with sparsely collected pharmacokinetic samples from individual patients in the study.</p><p>*Mean&nbsp;(Standard&nbsp;Deviation)&nbsp;calculated&nbsp;for&nbsp;patients&nbsp;2&nbsp;to&nbsp;6&nbsp;years&nbsp;of&nbsp;age,&nbsp;since&nbsp;no&nbsp;patients&nbsp;1&nbsp;to&nbsp;&lt;2years of age were enrolled in the study. Simulation using a population pharmacokinetic model&nbsp;demonstrated&nbsp;that&nbsp;the&nbsp;AUCSS&nbsp;(area&nbsp;under&nbsp;the&nbsp;concentration-time&nbsp;curve&nbsp;at&nbsp;steady&nbsp;state)&nbsp;ofdaptomycin&nbsp;in&nbsp;paediatric&nbsp;patients&nbsp;1&nbsp;to&nbsp;&lt;2&nbsp;years&nbsp;of&nbsp;age&nbsp;receiving&nbsp;12&nbsp;mg/kg&nbsp;once&nbsp;daily&nbsp;would&nbsp;becomparable&nbsp;to&nbsp;that</p><p>in&nbsp;adult&nbsp;patients&nbsp;receiving&nbsp;6&nbsp;mg/kg&nbsp;once&nbsp;daily.</p></td></tr></tbody></table><p>&nbsp;</p><ul><li><em>Obesity</em></li></ul><p>Relative to non-obese subjects daptomycin systemic exposure measured by AUC was about 28% higher in moderately obese subjects (Body Mass Index of 25-40 kg/m<sup>2</sup>) and 42% higher in&nbsp;extremely&nbsp;obese&nbsp;subjects&nbsp;(BodyMass&nbsp;Index&nbsp;of&nbsp;&gt;40&nbsp;kg/m<sup>2</sup>).&nbsp;However,&nbsp;no&nbsp;dose&nbsp;adjustment&nbsp;is considered to be necessary based on obesity alone.</p><ul><li><em>Gender</em></li></ul><p>No&nbsp;clinically&nbsp;significant&nbsp;gender-related&nbsp;differences&nbsp;in&nbsp;daptomycin&nbsp;pharmacokinetics&nbsp;have&nbsp;been&nbsp;observed.</p><ul><li><em>Renal&nbsp;impairment</em></li></ul><p>Following&nbsp;administration&nbsp;of&nbsp;a&nbsp;single&nbsp;4&nbsp;mg/kg&nbsp;or&nbsp;6&nbsp;mg/kg&nbsp;intravenous&nbsp;dose&nbsp;of&nbsp;daptomycin&nbsp;over a&nbsp;30-minute&nbsp;period&nbsp;toadult&nbsp;subjects&nbsp;with&nbsp;various&nbsp;degrees&nbsp;of&nbsp;renal&nbsp;impairment,&nbsp;total&nbsp;daptomycin clearance&nbsp;(CL)&nbsp;decreased&nbsp;and&nbsp;systemicexposure&nbsp;(AUC)&nbsp;increased&nbsp;as&nbsp;renal&nbsp;function&nbsp;(creatinine clearance) decreased.</p><p>Based&nbsp;on&nbsp;pharmacokinetic&nbsp;data&nbsp;and modelling,&nbsp;the&nbsp;daptomycin&nbsp;AUC&nbsp;during the&nbsp;first&nbsp;day after administration&nbsp;of&nbsp;a&nbsp;6mg/kg&nbsp;dose&nbsp;to&nbsp;adult&nbsp;patients&nbsp;on&nbsp;HD&nbsp;or&nbsp;CAPD&nbsp;was&nbsp;2-fold&nbsp;higher&nbsp;than&nbsp;that observed in adult patients with normal renal function who received the same dose. On the second day after administration of a 6 mg/kg dose to HD and CAPD adult patients the daptomycin&nbsp;AUC&nbsp;was&nbsp;approximately&nbsp;1.3-fold&nbsp;higher&nbsp;than&nbsp;that&nbsp;observed&nbsp;after&nbsp;a&nbsp;second&nbsp;6mg/kg dose in adult patients with normal renal function. On this basis, it is recommended that adult patients on HD or CAPD receive daptomycin once every 48 hours at the dose recommended for the type of infection being treated (see section 4.2).</p><p>The&nbsp;dosage regimen for daptomycin in&nbsp;paediatric patients&nbsp;with&nbsp;renal&nbsp;impairment&nbsp;has&nbsp;not&nbsp;been&nbsp;established.</p><ul><li><em>Hepatic&nbsp;impairment</em></li></ul><p>The pharmacokinetics of daptomycin is not altered in subjects with moderate hepatic impairment (Child-Pugh B classification of hepatic impairment) compared with healthy volunteers matched for gender, age and weight following a single 4 mg/kg dose. No dosage adjustment is necessary when administering daptomycin in patients with moderate hepatic impairment. The pharmacokinetics of daptomycin in patients with severe hepatic impairment&nbsp;(Child-Pugh C classification) have not been evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin administration was associated with minimal to mild degenerative/regenerative changes in skeletal muscle in the rat and dog. Microscopic changes in skeletal muscle were minimal (approximately 0.05% of myofibres affected) and at the higher doses were accompanied by elevations in CPK. No fibrosis or rhabdomyolysis was observed. Depending on&nbsp;the&nbsp;study&nbsp;duration,&nbsp;all&nbsp;muscle&nbsp;effects,&nbsp;including&nbsp;microscopic&nbsp;changes,&nbsp;were&nbsp;fullyreversible&nbsp;within 1-3 months following cessation of dosing. No functional or pathological changes in smooth or cardiac muscle were observed.</p><p>The&nbsp;lowest&nbsp;observable&nbsp;effect&nbsp;level&nbsp;(LOEL)&nbsp;for&nbsp;myopathy&nbsp;in&nbsp;rats&nbsp;and&nbsp;dogs&nbsp;occurred&nbsp;at&nbsp;exposure levels of 0.8 to 2.3-fold the human therapeutic levels at 6 mg/kg (30-minute intravenous infusion) for&nbsp;patients with normal renal function. As the pharmacokinetics (see&nbsp;section 5.2)&nbsp;is comparable, the safety margins for both methods of administration are very similar.</p><p>A study in dogs demonstrated that skeletal myopathy was reduced upon once daily administration as compared to fractionated dosing at same total daily dose, suggesting that myopathic effects in animals were primarily related to time between doses.</p><p>Effects&nbsp;on peripheral&nbsp;nerves&nbsp;were&nbsp;observed at&nbsp;higher&nbsp;doses than&nbsp;those&nbsp;associated&nbsp;with&nbsp;skeletal&nbsp;muscle effects in adult rats and dogs and were primarily related to plasma Cmax. Peripheral&nbsp;nerve&nbsp;changes&nbsp;were&nbsp;characterised&nbsp;byminimal&nbsp;to&nbsp;slight&nbsp;axonal&nbsp;degeneration&nbsp;and&nbsp;were&nbsp;frequently accompanied by functional changes. Reversal of both the microscopic and functional effects was complete within 6 months post-dose. Safety margins for peripheral nerve effects in rats&nbsp;and dogs are 8- and 6-fold, respectively, based on comparison of Cmax&nbsp;values at the No Observed Effect Level (NOEL)&nbsp;with the&nbsp;Cmax&nbsp;achieved on dosing with 30-minute&nbsp;intravenous&nbsp;infusion of 6 mg/kg once daily in patients with normal renal function.</p><p>The findings of&nbsp;<em>in vitro&nbsp;</em>and some&nbsp;<em>in vivo&nbsp;</em>studies designed to investigate the mechanism of daptomycin myotoxicity indicate that the plasma membrane of differentiated spontaneously contracting muscle cells is the target of toxicity. The specific cell surface component directly targeted has not been identified. Mitochondrial loss/damage was also observed; however the role and significance of this finding in the overall pathology are unknown. This finding was not associated with an effect on muscle contraction.</p><p>In&nbsp;contrast&nbsp;to&nbsp;adult&nbsp;dogs,&nbsp;juvenile&nbsp;dogs&nbsp;appeared&nbsp;to&nbsp;be&nbsp;more&nbsp;sensitive&nbsp;to&nbsp;peripheral&nbsp;nerve&nbsp;lesions as&nbsp;compared&nbsp;toskeletal&nbsp;myopathy.&nbsp;Juvenile&nbsp;dogs&nbsp;developed&nbsp;peripheral&nbsp;and&nbsp;spinal&nbsp;nerve&nbsp;lesions at doses lower than those associated with skeletal muscle toxicity.</p><p>In&nbsp;neonatal&nbsp;dogs,&nbsp;daptomycin&nbsp;caused&nbsp;marked&nbsp;clinical&nbsp;signs&nbsp;of&nbsp;twitching,&nbsp;muscle&nbsp;rigidity&nbsp;in&nbsp;the limbs,&nbsp;and&nbsp;impaireduse&nbsp;of&nbsp;limbs,&nbsp;which&nbsp;resulted&nbsp;in&nbsp;decreases&nbsp;in&nbsp;body&nbsp;weight&nbsp;and&nbsp;overall&nbsp;body condition&nbsp;at doses &ge;50 mg/kg/day&nbsp;and necessitated early discontinuation&nbsp;of treatment in these dose groups. At lower dose levels (25 mg/kg/day), mild and reversible clinical signs of twitching and one incidence of muscle rigidity were observed without any effects on body weight.&nbsp;There&nbsp;was&nbsp;no&nbsp;histopathological&nbsp;correlation&nbsp;in&nbsp;the&nbsp;peripheral&nbsp;and&nbsp;central&nbsp;nervous&nbsp;system tissue, or in the skeletal muscle, at any dose level, and the mechanism and clinical relevance for the adverse clinical signs are therefore unknown.</p><p>Reproductive toxicity testing showed no evidence of effects on fertility, embryofoetal, or postnatal development. However, daptomycin can cross the placenta in pregnant rats (see section 5.2). Excretion of daptomycin into milk of lactating animals has not been studied.</p><p>Long-term carcinogenicity studies in rodents were not conducted. Daptomycin was not mutagenic or clastogenic in a battery of&nbsp;<em>in vivo&nbsp;</em>and&nbsp;<em>in vitro&nbsp;</em>genotoxicity tests.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium&nbsp;Hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
After reconstitution: Chemical and physical in-use stability of the reconstituted solution in the vial has been demonstrated for 12 hours at 25°C and up to 48 hours at 2°C – 8°C. Chemical and physical stability of the diluted solution in infusion bags is established as 12 hours at 25°C or 24 hours at 2°C – 8°C.
For the 30-minute intravenous infusion, the combined storage time (reconstituted solution in vial and diluted solution in infusion bag; see section 6.6) at 25°C must not exceed 12 hours (or 24 at 2°C – 8°C).
For the 2-minute intravenous injection, the storage time of the reconstituted solution in the vial (see section 6.6) at 25°C must not exceed 12 hours (or 48 at 2°C – 8°C).
However, from a microbiological point of view the product should be used immediately. 
No preservative or bacteriostatic agent is present in this product. 
If not used immediately, in-use storage times are the responsibility of the user and would not normally be longer than 24 hours at 2°C – 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store&nbsp;at&nbsp;2&deg;C-8&deg;C</p><p>For&nbsp;storage&nbsp;conditions&nbsp;after&nbsp;reconstitution&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product,&nbsp;see&nbsp;section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin for Injection is a Pale yellow to light brown Lyophilised cake or powder for Injection containing 350 mg of Daptomycin per Vial.</p><p>The product is packed as 350 mg of&nbsp;Daptomycin in 15 mL USP Type I clear glass lyo vial, stoppered with 20 mm dark grey Bromobutyl rubber stoppers and sealed with 20 mm aluminium flip-off seals</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In&nbsp;adults,&nbsp;daptomycin&nbsp;may&nbsp;be&nbsp;administered&nbsp;intravenously&nbsp;as&nbsp;an&nbsp;infusion&nbsp;over&nbsp;30&nbsp;minutes&nbsp;or&nbsp;as an&nbsp;injection&nbsp;over&nbsp;2minutes.&nbsp;Daptomycin&nbsp;should&nbsp;not&nbsp;be&nbsp;administered&nbsp;as&nbsp;a&nbsp;2-minute&nbsp;injection&nbsp;to paediatric patients. Paediatric patients 7 to 17 years old should receive daptomycin infused over 30 minutes. In paediatric patients under 7 years old receiving a 9- 12 mg/kg dose, daptomycin should be administered over 60 minutes (see sections 4.2 and 5.2).</p><p>Preparation&nbsp;of&nbsp;the&nbsp;solution&nbsp;for&nbsp;infusion&nbsp;requires&nbsp;an&nbsp;additional&nbsp;dilution&nbsp;step&nbsp;as&nbsp;detailed&nbsp;below.</p><p>&nbsp;</p><p><u>Daptomycin&nbsp;TBM&nbsp;given&nbsp;as&nbsp;30&nbsp;or&nbsp;60-minute&nbsp;intravenous&nbsp;infusion</u></p><p>A 50 mg/ml concentration of Daptomycin TBM powder for infusion is obtained by reconstituting the lyophilised product with 7 ml of sodium chloride 9 mg/ml (0.9%) solution for injection. The lyophilised product takes approximately 15 minutes to dissolve. The fully reconstituted product will appear clear and may have a few small bubbles or foam around the edge of the vial.</p><p>To prepare Daptomycin TBM for intravenous infusion, please adhere to the following&nbsp;instructions:</p><p>Aseptic&nbsp;technique&nbsp;should be&nbsp;used throughout to reconstitute&nbsp;or&nbsp;dilute&nbsp;lyophilised Daptomycin&nbsp;TBM.</p><p><u>For&nbsp;Reconstitution:</u></p><p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;polypropylene&nbsp;flip&nbsp;off&nbsp;cap&nbsp;should&nbsp;be&nbsp;removed&nbsp;to&nbsp;expose&nbsp;the&nbsp;central&nbsp;portions&nbsp;of&nbsp;the rubber stopper. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface. Draw 7 ml of sodium chloride 9 mg/ml (0.9%) solution for injection into a syringe using a sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device, then slowly inject through the centre of the rubber stopper into the vial pointing the needle towards the wall of the vial.</p><p><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The vial should be gently rotated to ensure complete wetting of the product and then allowed to stand for 10 minutes.</p><p><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Finally,&nbsp;the&nbsp;vial&nbsp;should&nbsp;be&nbsp;gently&nbsp;rotated/swirled&nbsp;for&nbsp;a&nbsp;few&nbsp;minutes&nbsp;as&nbsp;needed&nbsp;to&nbsp;obtain a&nbsp;clear&nbsp;reconstitutedsolution.&nbsp;Vigorous&nbsp;shaking/agitation&nbsp;should&nbsp;be&nbsp;avoided&nbsp;to&nbsp;prevent&nbsp;foaming of the product.</p><p><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The reconstituted solution should be checked carefully to ensure that the product is in solution and visually inspected for the absence of particulates prior to use. Reconstituted solutions of Daptomycin TBM range in colour from pale yellow to light brown.</p><p><!--[if !supportLists]-->5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;reconstituted&nbsp;solution&nbsp;should&nbsp;then&nbsp;be&nbsp;diluted&nbsp;with&nbsp;sodium&nbsp;chloride&nbsp;9&nbsp;mg/ml&nbsp;(0.9%) (typical volume 50 ml).</p><p>&nbsp;</p><p><u>For&nbsp;Dilution:</u></p><p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Slowly remove the appropriate reconstituted liquid (50 mg daptomycin/ml) from the vial using a new sterile needle that is 21 gauge or smaller in diameter by inverting the vial in order&nbsp;to&nbsp;allow&nbsp;the&nbsp;solution&nbsp;to&nbsp;drain&nbsp;towards&nbsp;thestopper.&nbsp;Using&nbsp;a&nbsp;syringe,&nbsp;insert&nbsp;the&nbsp;needle&nbsp;into the inverted vial. Keeping the vial inverted, position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe barrel in order to remove the required solution from the inverted vial.</p><p><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Expel&nbsp;air,&nbsp;large&nbsp;bubbles, and&nbsp;any&nbsp;excess&nbsp;solution&nbsp;in&nbsp;order&nbsp;to&nbsp;obtain&nbsp;the&nbsp;required&nbsp;dose.</p><p><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Transfer&nbsp;the&nbsp;required&nbsp;reconstituted dose&nbsp;into&nbsp;50&nbsp;ml sodium&nbsp;chloride&nbsp;9&nbsp;mg/ml&nbsp;(0.9%).</p><p><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;reconstituted&nbsp;and&nbsp;diluted&nbsp;solution&nbsp;should&nbsp;then&nbsp;be&nbsp;infused&nbsp;intravenously over&nbsp;30&nbsp;or 60 minutes as directed in section 4.2</p><p>&nbsp;</p><p><u>Daptomycin&nbsp;TBM&nbsp;given&nbsp;as&nbsp;2-minute&nbsp;intravenous&nbsp;injection&nbsp;(adult&nbsp;patients&nbsp;only)</u></p><p>Water should not be used for reconstitution of Daptomycin TBM for intravenous injection. Daptomycin TBM should only be reconstituted with sodium chloride 9 mg/ml (0.9%).</p><p>A 50 mg/ml concentration of Daptomycin TBM injection is obtained by reconstituting the lyophilised product with 7 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.</p><p>The lyophilised product takes approximately 15 minutes to dissolve. The fully reconstituted product will appear clear and may have a few small bubbles or foam around the edge of the&nbsp;vial.</p><p>To prepare Daptomycin TBM for intravenous injection, please adhere to the following&nbsp;instructions:</p><p>Aseptic&nbsp;technique&nbsp;should be&nbsp;used&nbsp;throughout&nbsp;to&nbsp;reconstitute&nbsp;lyophilised&nbsp;Daptomycin&nbsp;TBM.</p><p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;polypropylene&nbsp;flip&nbsp;off&nbsp;cap&nbsp;should&nbsp;be&nbsp;removed&nbsp;to&nbsp;expose&nbsp;the&nbsp;central&nbsp;portions&nbsp;of&nbsp;the rubber stopper. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface. Draw 7 ml of sodium chloride 9 mg/ml (0.9%) solution for injection into a syringe using a sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device, then slowly inject through the centre of the rubber stopper into the vial pointing the needle towards the wall of the vial.</p><p><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The vial should be gently rotated to ensure complete wetting of the product and then allowed to stand for 10 minutes.</p><p><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Finally,&nbsp;the&nbsp;vial&nbsp;should&nbsp;be&nbsp;gently&nbsp;rotated/swirled&nbsp;for&nbsp;a&nbsp;few&nbsp;minutes&nbsp;as&nbsp;needed&nbsp;to&nbsp;obtain a&nbsp;clear&nbsp;reconstitutedsolution.&nbsp;Vigorous&nbsp;shaking/agitation&nbsp;should&nbsp;be&nbsp;avoided&nbsp;to&nbsp;prevent&nbsp;foaming of the product.</p><p><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The reconstituted solution should be checked carefully to ensure that the product is in solution and visually inspected for the absence of particulates prior to use. Reconstituted solutions of Daptomycin TBM range in colour from pale yellow to light brown.</p><p><!--[if !supportLists]-->5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Slowly remove the reconstituted liquid (50 mg daptomycin/ml) from the vial using a sterile needle that is 21 gauge or smaller in diameter.</p><p><!--[if !supportLists]-->6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Invert the vial in order to allow the solution to drain towards the stopper. Using a new syringe, insert the needle into the inverted vial. Keeping the vial inverted, position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe&nbsp;barrel&nbsp;in&nbsp;order&nbsp;to&nbsp;remove&nbsp;all&nbsp;of&nbsp;the&nbsp;solution&nbsp;from&nbsp;the&nbsp;inverted&nbsp;vial.&nbsp;Replaceneedle&nbsp;with a new needle for the intravenous injection</p><p><!--[if !supportLists]-->7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Expel&nbsp;air,&nbsp;large&nbsp;bubbles, and&nbsp;any&nbsp;excess&nbsp;solution&nbsp;in&nbsp;order&nbsp;to&nbsp;obtain&nbsp;the&nbsp;required&nbsp;dose.</p><p><!--[if !supportLists]-->8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;reconstituted&nbsp;solution&nbsp;should&nbsp;then&nbsp;be&nbsp;injected&nbsp;intravenously&nbsp;slowly&nbsp;over&nbsp;2&nbsp;minutes as directed in section 4.2.</p><p>&nbsp;</p><p>Daptomycin&nbsp;TBM&nbsp;vials&nbsp;are&nbsp;for&nbsp;single-use&nbsp;only.</p><p>From&nbsp;a&nbsp;microbiological&nbsp;point&nbsp;of&nbsp;view,&nbsp;the&nbsp;product&nbsp;should&nbsp;be&nbsp;used&nbsp;immediately&nbsp;after reconstitution (see section 6.3).</p><p>Any unused medicinal product or waste material&nbsp;should be&nbsp;disposed of in accordance with&nbsp;local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company,
Sudair Industrial Zone, 
Sudair,
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>